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RÉSUMÉ
Les corticotropes sont les premières cellules à se différencier dans l’hypophyse
embryonaire. Des expériences d’explants suggèrent un role négatif pour les signaux Brnps
dans la différenciation corticotropique, tandis que des études de gain-de-function suggèrent
le contraire. POMC étant un marqueur corticotropique, mon projet de maîtrise a porté sur
le rôle des signaux Bmp dans l’expression de POMC. Je démontre que l’expression de
POMC décroit dans les cellules AtT-20, suite à des traitements avec des protéines Bmp-4
recombinantes ou à la surexpression de composantes de la voie des Bmp/Smad, soient les
récepteurs Alk-3/-6 et les facteurs de transcription $madl/4. La surexpression des
inhibiteurs Smad6 et Smad7 renversent cette répression. L’effet négatif de Bmp sur le
promoter POMC nécessite les éléments de réponse Pitx et Tpit, et interfère avec l’activité
synergique des deux protéines. Des interactions in vitro entre Pitxl, Tpit et Srnadl
appuient un mécanisme d’action des Smads qui passerait directement par Pitx et Tpit.
Mots clés : différenciation cellulaire, signalisation, répression, transcription, hormone
et Tgf-f3.
iv
SUMMARY
Corticotrophs constitute the first hormone-producing ceil type to emerge in the
developing pituitary. Tissue expiant experiments had suggested a negative role for Bone
morphogenic-protein (Bmp) signais in corticotroph differentiation, but transgenic studies
had argued against this. Seeing that proopiornelanocortin (POMC) expression is a hallmark
of corticotrophs, my Master’s project consisted in studying the roie of Brnp signaiing on
POMC transcription. I found that POMC expression was downreguiated in AtT-20
corticotroph celis that either underwent recombinant (r)Bmp-4 treatments or were
transientiy transfected with Alk-3/-6 constitutiveiy activated Bmp-type I receptors or
Smadl/4 effector proteins. Overexpression of Smad6 or Smad7 counteracted this
inhibitory Bmp signaling. Corticotroph-specific functions had previously been assigned to
Pitx, Tpit and NeuroD 1 transcription factors. I show that Bmp action on POMC prornoter
requires Pitx and Tpit reguiatory eiements, and appears to be exerted by directiy repressing
Pitx/Tpit synergistic activities. In vitro interactions between Pitxl, Tpit and Smadl support
the latter mechanisnt
Key words: celi differentiation, signalisation, repression, transcription, hormone and
Tgf-.
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CHAPTER- 1 INTRODUCTION
1.1 Corticotrophs in the Mature Pituitary
The pituitary gland, also known as the hypophysis, is a specialized neuroendocrine
organ that coordinates the control of peripheral physiology in response to stimuli derived
from the brain and other endocrine glands. It can be divided rnorphologically and
functionally into an anterior and intermediate lobe, which together constitute the
adenohypophysis, and a posterior lobe known as the neurohypophysis. Corticotroph celis
are found in the anterior lobe, and they principally produce adrenocorticotropin honnone
(ACTH) by proteolytic processing of proopiomelanocortin (POMC). Adrenocortin
(ACTH) is well known for its role in the regulation of the stress response by increasing the
production of cortisol from the adrenal gland (108). Meianotroph celis, located in the
intermediate lobe, also express the FOMC precursor gene, which is processed in a different
manner to generate a-melanocyte-stimulating hormone (u-MSH). The intermediate
pituitary is well-defined in rodents, but degenerates after birth in higher animais, inciuding
humans wherein Œ-MSH is essentially produced by extrapituitary cells (115).
Melanocortin (Œ-MSH) was initially characterized as a regulator of skin pigmentation by
inducing the production of melanin from keratinocytes. It is now known to be a general
modulator of skin biology and pathology (151)and (150).
four other hormone-producing cells are present in the pituitary anterior lobe;
nameiy, prolactin (PRL)-secreting lactotrophs, thyroid-stimulating hormone (TSH)
secreting thyrotrophs, luteinizing hormone (LH)- and follicle-stimulating hormone (F$H)
secreting gonadotroplis, and growth hormone (GH)-secreting somatotrophs. These
hormones regulate such functions as body growth (GH), rnamrnary growth and
2developrnent (PRL), as well as thyroid gland (TSH) and gonad (LH and FSH) functions
(121). The neuropituitary hormones oxytocin and vasopressin, secreted from nerve endings
in the neurohypophysis, serve homeostatic functions in water balance and repi-oduction,
respectively (25).
1.2 Pituïtary Organogenesis
1.2.1 Developmental Origin ofthe Pituitary
The pituitary gland is composed of tissues of two embryologicaly distinct origins:
the adenohypophysis consisting of epithelial or glandular celis derives from ectodermal
tissue, and the neurohypophysis is of neuroectodermal origin (217). Pituitaiy developrnent
in the mouse occurs in a midiine region of oral ectoderrn or stomodeum that contacts
neuroectoderm (ventral diencephalon) destined to become the floor of the forebrain (Figure
1.1). By embryonic day 9 (e9.O), the oral ectoderm involutes to form the pituitary
rudiment, Rathke’s pouch. In what is probably the first complete anatomical account of
early pituitary development (217), Schwind describes Rathke’s pouch of rat as a structure
that arises from an invagination of the stomodeal ectoderm. The idea tliat Rathke’s pouch
actively folds in to meet up with the neuroepithelium dorsally lias since been challenged.
Through studies performed in quail/chick chimeras (41), Bufo albino/wild-typc chimeras
(111) and mouse embryos (117), it was dernonstrated that contact between oral ectoderm
and ventral diencephalon layers in the developing brain is sustained only at the level of the
pituitary rudiment. Rather tlian invaginating, Rathke’s pouch merely appears to take an
inward fold, because of rnaintained contact at pituitary level when everywhere else surface
ectoderm and neuroepithelium get separated by invading mesenchyrne of pre-chordal plate
and neural crest origin. At the same time, the overlaying ventral diencephalon grows
downward to generate the infundibulum destined to become the neurohypophysis.
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41.2.2 Pituitary Primordium Induction
Rathke’s pouch formation requires that the pituitary prirnordium receive and
correctly process inductive signais coming from the ventral diencephalon (44). Expression
pattem studies have demonstrated Bone morphogenic protein (Bmp)-4, Fibroblast growth
factor (Fgf)-$, and Fgf-1O to be expressed in a restncted region of the ventral diencephalon
that is in direct contact with the pituitary primordium (244) (67). Bmp-4 expression is
detectable in the ventral diencephalon by e8.5, prior to the appearance of Fgf-8 (Figure
1.1), suggestive of a role for Bmp-4 in the earliest phases of pituitary development. The
compiete lack of pituitary rudiment in a smaii population of Bmp-4 mice that survived to
elO, a time at which Rathke’s pouch formation is normally weil under way, support a role
for Brnp-4 signaling in the induction of the pituitary primordiurn (237). The possibility that
conveyance of another inductive signal might have been affected in these Bmp-4 gene
deleted mice is unlikely since contact between ventral diencephalon and oral ectoderm was
rnaintained in the absence of Bmp-4. Such a penetrating phenotype was however not
obsewed in mice upon ectopic expression of Noggin, a Bmp-specific antagonist (174), in
Rathke’s pouch and oral ectoderm using the Fitxl promoter. Pituitary development in these
Fitxl-Noggin transgenic mice was abrogated only afier the rudimentary pouch had formed
(244). A partial blockade of Brnp-4 function by Noggin could be to blame for the
discrepancy with Bmp-4’ embryos.
1.2.3 Rathke’s Pouch Formation
Formation ofRathke’s pouch from the oral ectoderm also appears to be controlled
by Fgf and Sonic hedgehog (Shh) signals. Fgf-8 and Fgf-1O have been shown to be
expressed in the ventral diencephalon at the time (e9.5) ofpouch formation (22). In fgf10
nuil mice, pituitary development is blocked right afler formation of the rudimentary pouch
5(187). Fgfr-2(IIIb), a receptor that bas been demonstrated to have good binding affinity for
Fgf-10 and that has moreover been detected in Rathke’s pouch (237), is thought to mediate
Fgf signaling within the oral ectoderm. Indeed, Fgfr-2(IIIb) gene deleted mice exhibit an
arrest in pituitary development that is similar to that observed in fgf-]0’ mice (50).
Targeted disruption of the homeobox gene T/ebp, expressed during early development in
the ventral diencephalon, also resulted in disruption of pituitary development subsequent to
a loss of the neuroectodermal region of Fgf-8 expression (237). However,
dysmorphogenesis of the vental diencephalon in these T/ebp nuli mice poses a problem in
interpreting a direct role for Fgf-$ in pituitary organogenesis.
Two reiated transcription factors are postulated to mediate fgf early signais, the
Lim horneobox proteins Lhx-3 and Lhx-4 which are both expressed specifically in the
pituitary rudiment by the time Rathke’s pouch formation begins (e8.5). hi vitro
experiments have shown that Fgf-$ lias the ability to maintain Lhx-3 expression (67). li
the absence of both Lhx-3 and Lhx-4, mutant mice show no more than a rudiment of
Rathke’s pouch (219)as do fgf]OE’ and fgfr(2111b7’ mice. Yet, neither Lhx-3 (220)or
Lhx-4 (219) single mutant mice exhibit such a pronounced phenotype, each single mutant
pituitary developing into a glandular structure. Hence, the presence of either Lhx-3 or Lhx
4 seems to be required for the progression ofpituitary developrnent beyond the rudimentary
stage.
Shh is expressed in surrounding oral ectoderm, mesenchyme and diencephalon,
but is specificaïly excluded ftom Rathke’s pouch (244) (245). Gene deleted mice for Shh
have not been usefui to understand the role of Shh in pituitary development since total ioss
of hedgehog function altogether interferes witli the establishment of ventral dienceplialic
contacts with the pituitary primordium (245). The significance of Shh signaling was
studied using Fitx]-Hip transgenic mice; nameiy, Pitx] promoter sequences known to
6target gene expression to the oral ectoderm and Rathke’s pouch were used to ectopicaly
express the hedgehog-specific inhibitor Hip (245). This block in pituitary hedgehog
signaling interfered with progression beyond rudimentary pouch development. A direct
role for Shh in Rathke’s pouch formation was nonetheless suggested by the Pitxl-Hip
experiment since the expression domain ofFgf-8 was flot disrupted in presence of an intact
ventral diencephalon.
1.3 Pituitary Ceil Expansion ami Differentiation
The six celi types of the anterior pituitary exhibit an ontogenic pattem of hormone
gene expression that follows a defined temporal, and sornewhat spatial sequence of
appearance (100). The first sign ofpituitary ceil fate commitment cornes at elL5 with the
appearance of a-GSU transcripts on the ventral side of the expanding anterior pituitary
(Figure 1.2). Corticotroph celi specification, marked by the appearance of POMC/ACTH at
e12.5 in the mouse anterior pituitary, appears nonetheless to precede the specification of
any other celi lineage in the developing pituitary. Melanotrophs, which constitute the other
lineage of POMC-expressing ceils in the pituitary, differentiate later as POMC/MSH are
detected only at e 14.5 in the intermediate pituitary. A transient population of thyrotroplis,
identified by expression of the TSH-3 subunit, appear on e13 in the rostral end of the
anterior pituitary (138). They will disappear after birth. A second cluster of TSH3-
expressing thyrotrophs appears on e14.5, and represents the terrninally differentiated
thyrotrophs, followed by the contemporaneous expression of GH (somatotrophs) and PRL
(lactotrophs) on e16. Gonadotroph-specific LH-13 and FSH-13 transcripts finally appear at
e16.5 and e17.5, respectively.
The specification and expansion of ceil fates from a common pituitary primordium
has been proposed to be the consequence of overlapping expression pattems of specific sets
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8of extrinsic growth and intrinsic transcription factors, expressed in a precise spatiotemporal
manner during organogenesis. One approach to understanding the molecular mechanisms
that mediate the emergence of pituitary ceil types is to study promoter elernents implicated
in the regulation of hormone marker gene expression (Figure 1.2), as transcription factors
conferring cell-specificity are also often implicated in celi differentiation.
Pituitary celis can be classified into three groups according to similarities between
components mediating their distinct differentiation pathways. One group is comprised of
somatotrophs and lactotrophs, another of thyrotrphs and gonadotrophs, and yet another of
corticotrophs and melanotrophs. A paraïlel can be made between group members with
regards to their hormone structure and developrnental origin.
1.3.1 Somatotroplis and Lactotroplis
On the basis of primary structure and biological function similarities, GH and PRL
have been grouped together with the related placental lactogen (PL) in the PRL/GH/PL
family. GH, FRL and FL genes are thought to have arisen from a common ancester by
gene duplication and evolutionary divergence (23,33). CelIs that secrete both GH and PRL,
known as mammosomatotrophs, have been identified in neonate and aduit rats by reverse
hemolytic plaque assays (27) and inirnunocytochemistry (29,29). Gene ablation techniques
specifically targeting GH-expressing celis in the developing pituitary have shown an almost
complete absence of both somatotrophs and lactotrophs in transgenic mice, reinforcing the
concept of a stem-somatotroph as common precursor to somatotroph and lactotroph ccli
populations. Also, sornatomaminotropic pituitary tumors are quite common (33).
1.3.1.1 Somatomammotropic Piti- and Propi-dependent differentiation pathway
The molecular basis of somatotroph and iactotroph ccli differentiation implicates
the activities of the pituitary-specific horneodomain protein Pit-1. Pit-1 expression is
9detected at e13.5 in a region of the pituitary from which sommatotrophs and lactotrophs
arise (100). Experiments have shown that Pit-1 mRNA transcripts are actually expressed at
the same level in ail pituitary ceil types, but translated to significant protein levels only in
somatotrophs, lactotrophs and thyrotrophs (230). Initiaily identified as Growth Hormone
Factor- 1 (GHF- 1), Pit- 1 was cloned as a transactivator of FR1 and GH gene promoters
(97,240).
The importance of Pit-1 as a regulator of somatotroph and lactotropli
differentiation was demonstrated by the absence of these two celi types in the pituitary
glands of $nell (dw) and Jackson (dw) dwarf strains of mice in which the Fit-1 gene is
mutated (6,35,135). Acting upstream in the differentiation pathway ofPit-1 is the pituitary
specific paired-like homeodomain factor Prophet of Pit-1 (PROP-1), detected in Rathke’s
pouch from elO.5 to e 16.0 (225). Prop-] mutations were identified in the Ames (df) dwarf
mouse, which moreover exhibits defective Fit-1 gene expression and shares phenotypic
defects with dw and dwJ FUi-mutant mice. Pituitary hypoplasia in dw, dw and df dwarf
strains of mice is in support of a role for PROP-1 and Pit-1 not oniy in the establishement
and maintenance of differentiated phenotypes, but aiso in the proliferation of precursor
cells (135,225). How ceil proliferation signais are coupied to celi commitment and
differentiation signais during pituitary development remains to be eiucidated. In hurnans,
PROF-1 mutations have been characterized in and related to an absence or low leveis of
GH, PRL, T$H, LH, FSH and recently ACTH (183) in human combined pituitary hormone
deficiency (CPHD) (64).
1.3.1.2 Cooperation between Pit-1 and Nuclear Receptors
Extensive analysis of rat and human GH gene reguiatory elements have implicated
Pit-l binding and ensuing cooperation with retinoic acid receptor (RAR), thyroid hormone
nuclear receptor (TR), and the zinc finger Zn- 15 protein in effective sornatotroph-specific
10
expression (40,140). Pit-1 is believed to direct lactotropli-specific PRL gene expression by
collaborating with estrogen nuclear receptor (ER), as weÏl as Ets and Pitx factors
(42,48,248).
1.3.1.3 Pitx Homeobox Proteins Collaborate with Piti
The homeobox Pitx 1 and Pitx2 transcription factors are other general regulators of
pituitary-specific transcription, including GH and PRL gene expression (Figure 1.2). Pitx 1
was identified as a transcriptional regulator of POMC gene expression (12$), and also as a
factor interacting with Pit-1 (235). Fitx2 was isolated as the causative gene by
haploinsufficiency for Rieger’s syndrome (21$). Pitxl and Pitx2 expression defines the
oral ectoderm as early as e$.0, and is rnaintained in derivative structures throughout
pituitary development (129,137). In addition to their pan-pituitary expression, Pitxl and
Pitx2 are expressed in distinct regions of the embryo. Their complex pattern of expression
is consistent with the roles of Pitxl in such developmental processes as craniofacial and
limb development, and the roles of Pitx2 in establishment of laterality, as well as heart,
Iting, and craniofacial development (129,137,234). These roles will not be discussed
further. The last member of the Pitx subfamily, Pitx3, is flot expressed in the pituitary
(132) which suggests that it does flot play a role in pituitary functions.
Pitxl and Pitx2 have sirnilar transcriptional activities on POMC, a-GSU, LH-/3,
FSH-/3, TSH-fi, PRL, and GH pituitary-specific promoters (247). Their pan-pituitary
expression, and contribution to ceil-specific transcription of many pituitary specific genes
may reflect the common origin of pituitary celis. Like Pit- 1, Pitx factors are thought to
confer promoter-specific expression through synergistic interactions with cell-restricted
factors. With respect to sommatolactotroph ceil differentiation, Pitxl was shown to
cooperate not only physically, but also transcriptionally with Pit-1 on the GH and PRL
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promoters (235,248). Pitx] -loss-of-function expenments did flot significantly affect the
expression levels of either GH or PRL (130,234) as Pitx2 is thought to have compensated
for pituitary ceil differentiation functions. Such a role for Pitx2 in the differentiation of the
sornrnatolactotroph ceil lineage couli flot be studied in Pitx2 mice because of premature
pituitary developmentaÏ arrest (137).
1.3.2 Ihyrotrophs ami Gonadotrophs
The glycoprotein hormones LH, FSH and TSH are heterodirners cornposed of a
common Œ-glycoprotein subunit (a-GSU) noncovaÏently assernbled with respective
hormone-specific 13-subunits LH-13, FSH-13, or T$H-f3. The f3-subunit confers hormone
specificity, while the Œ-subunit is homologous within a species. Phylogenetic studies using
nucleotide and arnino acid sequence alignrnents predict that both Œ- and f3-subunits evolved
from a single ancestor through gene duplication (134). During pituitary development,
thyrotrophs are thought to derive from a pool of precursor ceils that also give rise to
sommatotrophs and lactotrophs, but not gonadotrophs. In a-GSU gene-deleted mice,
hyperpiasia and hypertrophy of TSH-positive cells as a resuit of thyroid dysfunction was
accompanied by a reduction of GH and PRL celis (49).
1.3.2.1 Interplay between Pit-1 and GATA-2 Activities
Although thyrotrophs and gonadotrophs do not seem to share a common precursor,
reciprocal interactions between Pit-1 and the zinc finger protein GATA-2 would be
implicated in the specification of both cell types (46). Differential GATA-2 function in
these two celi types is defined by extrinsic Bmp2 and Shh signaling (46,245). Bmp2
signals are detected in the ventral juxtapituitary mesenchyrne (VJM) as well as in the
ventral region of the committed pituitary around e 12.5, while Shh is expressed around but
not in the pituitary (67,244). Transgenic studies have shown that gonadotroph- and
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thyrotroph-specific GATA-2 expression is induced by BMP-2, itselfinduced by Shh (245).
Elevated GATA-2 expression levels have been associated with the inhibition of
endogenous Pit-1 gene expression in gonadotrophs (46,244). Expanding GATA-2
expression under the control ofPit-1 regulatory elements in transgenic mice is sufficient to
convert ail Pit-1 dependent lineages to the gonadotroph fate (46). In thyrotrophs, lower
levels of GAlA-2 are not believed to interfere with Pit-1 expression; in these ceils, Pit-1
and GAlA-2 were shown to interact and functionally cooperate to activate the TSH-fi
promoter (73). In thyrotrophs, Pit-i is moreover thought to function to inhibit GATA-2
binding and activation ofLH and FSH regulatory elements that do not contain adjacent Pit
1 binding sites. The ability of Pit-1 to interfere with GAlA-2 function is lost in Snell dw
mice that have a W48C mutation in the Pit- 1 POU homeodomain which dismpts Pit
1/GATA-2 interactions, causing thyrotrophs to assume a gonadotroph fate (46).
1.3.2.2 Celi-Specific Collaboration ofPïtx Factors with Egr-1, SF-, Spi and Lhx
Factors
In pituitaries of Pitxl-deleted mice, LH-, FSH-J3 and TSH-3 levels are severily
reduced, suggesting that Pitxl is required for expression and/or maintenance of
gonadotroph and thyrotroph lineages (130,234). The Pitxi binding site in the LH-/3
promoter was dernonstrated to be essential for its activity in vivo; transgenic mice
harbouring a mutation of the Pitxl binding site in the LH-fl promoter lost basal as well as
Gonadotropin-Realesing Hormone (GnRH)-stirnulated pituitary expression (201). GnRH is
a critical hypothalamic peptide that is required for the production and secretion of
gonadotropins LH and FSH (54). Along with Pitxl, the zinc finger protein Early response
1 (Egr- 1) and Spi proteins, as welI as nuclear receptor steroidogenic factor- 1 (SF- 1) have
been shown to coordinate the complex control of basal andlor GnRH-stimulated LH-fi gene
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promoter activity (105,246). In both Egri- and $f1-deficient mice, LH-Ç3 production was
compromised (98,153,243). Expression 0f FSH-13 was also absent in Sf-] pituitaries. It
appears that LH and FSH deficiencies in $FF’ mice may be rnediated by defective GnRH
expression in hypothalamus (98). The integration of Pitxl in previously described
synergistic functions of GATA-2 and Pit-1 on the T$H-/i promoter is stili poorly
understood.
Pitx and Lhx factors, via the actions of Lim-associated cofactor (CLIM), have
been implicated in gonadotroph-specific activity of the bovine a-G$U promoter (9,109).
Distinct cis-acting elements, stiil undefined, are thought to regulate a-GSU expression in
thyrotrophs (49).
1.3.3 Corticotroplis and Melanotroplis
Both anterior lobe corticotrophs and intermediate lobe melanotrophs express and
transcribe the POMC gene, beginning in mice at e12.5 in corticotroplis and at e14.5 in
melanotrophs (100). A POMC cDNA was originally obtained from the intermediate lobe of
bovine pituitaries (175), and since then the POMC gene has been cloned in rat (59), human
(236), and mouse (185) among other species. Two introns and three exons make up the rat
POMC gene (figure 1.3), which measures approximately 6.5 kilobases (kbs). A mature
1200 nucleotide POMC mRNA transcript is found in the pituitary as a result of gene
spticing (62). It is essentially the same transcript that is translated in corticotrophs and
melanotroplis, but the resulting POMC peptide prohormone is subsequently processed in a
different manner in each celi type by distinct cohorts of protein convertases (PC). ACTH
resuits from corticotroph PCi proteolytic activity, and the additional PC2 in rnelanotrophs
processes ACTH further into Œ-MSH and CLIP (11). ACTH, -1ipotropin, and 3-
endorphin are the principal hormone end-products ofPOMC generated in corticotrophs,
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while POMC is processed further into Œ-MSH, CLIP, and -endorphin in melanotrophs
(152). Processing into ACTH depends on the PCi proteolytic activity; the additional
activity ofPC2 in mclanotrophs processes ACTH ftirther into Œ-MSH and CLIP (11).
1.3.3.1 Contribution of Pitx Factors to POMC Lineages
In the end, single Pitx gene ablation experiments have not proven to be useful in
assessing the actual need for Pitx activity for corticotroph and melanotroph ccli function.
In neither Pitxi’ nor Pitx2 mice was POMC expression affected (130,137,234),
suggesting that POMC expression in vivo would require either Pitx gene activity.
Pitx]/Pit2 double knock-outs could have been more informative in this case. However, the
premature block in pituitary development observed in the latter double nuil mice has made
the study ofpituitary ceil differentiation impossible (229).
Clues on the contribution of Pitx factors to the specification of corticotroph, and
possibly melanotroph ccli fates, have been provided by studies perfomied on the POMC
promoter in AtT-20 corticotroph ccli model. An account of POMC gene transcription
studies will be given below. It is worth mentioning at this point the central position that
Pitx factors hold in mediating protein interactions with two major determinants of the
corticotroph ccii fate; that is, the bHLH factor NeuroDiand the newly characterized T-box
factor Tpit.
1.3.3.2 NeuroDi, an Exclusive bHLH Factor for Cortïcotrophs
The bHLH class of transcription factors lias been studied extensively for their role
in myogenic and neurogenic processes, as tissue-specific regulators of ccii specification.
NeuroDi is a neuro- and pancreatic-islet-specific bHLH transcription factor implicated in
neuronal precursor differentiation and tissue-specific expression of the insutin gene,
respectively (133,17$). The expression of NeuroDi is transient in the developing mouse
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pituitary, present between e12 and e15, but not afler e16 (198); moreover, its expression is
restricted to corticotrophs. NeuroDi mRNA but flot protein can be detected in the aduit
mouse (199). NeuroDi transcripts have also been detected in normal hurnan pituitaries and
in ACTH-secreting pituitary adenomas (191). NeuroDl expression preceedes that of
POMC in differentiating corticotrophs, inferring a role for NeuroDi in the induction of
corticotroph differentiation. NeitroDi nuil mice did not exhibit a significant loss of
pituitary POMC expression when analyzed at e17.5. However, a delay in the appearance of
POMC expression in the anterior pituitary of NeuroDT’ mice was recorded at earlier times
(e14.5), suggesting that NeuroDi participates but is not essential for the onset of
corticotroph differentiation (Lamolet B, unpublished). NeuroDl has been demonstrated to
confer corticotroph-specific activity to the POMC promoter through synergistic interactions
with Pitxl, the details ofwhich are discussed below.
1.3.3.3 Conversion of POMC Ceils into POMC1 Celis by the T-box Factor Tpit
T-box factors are defined by a conserved DNA-binding motif known as the T-box,
named afier the first-discovered T-box gene T or Brachytuy (255). Members of this farnily
of transcription factors have been identified in both vertebrates and invertebrates, where
they have been implicated in developrnental decisions concerning patteming (224)and
recently celi differentiation (127,233). Tpit expression studies have shown that it is
restricted to corticotroph and melanotroph POMC-expressing celis in the developing
pituitary and precedes POMC expression in each cell type by 0.5 days, suggesting a role for
this factor in corticotroph and melanotroph differentiation. Transgenic expression of Tpit
under the control of the a-GSU promoter was sufficient to induce expression of POMC in
ceils ofthe rostral tip ofthe developing pituitary (127). This particular structure contains a
population oftransient, proliferating, uncornmitted cells (179) that do flot normally express
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POMC but express high levels of Pitxl (129). Hence, Tpit appears sufficient to induce
POMC transcription in Pitx-1-expressing uncomrnitted pituitary cells (Figure 1.4). The
expression of the corticotroph marker NeuroDi was not induced in these ectopic POMC
expressing celis, indicating that additional information is required for terminal
differentiation into corticotrophs.
1.3.3.3.1. Isolated ACTH Deficiency
In humans, POMC is expressed in three tissues: in the anterior pituitary to
stimulate cortisol production by the adrenal gland (the intermediate pituitary degenerates
afier birth in humans), in the hypothalamus to regulate appetite via the leptin pathway, and
in skin where it plays a role in pigmentation and cutaneous inflammation. Genetic defects
in the POMC gene have been identified (122). Consistent with the expression pattem of
POMC, these patients suffer from adrenal insufficiency, early onset obesity and red hair
pigmentation. The lack of a-MSH peptide in POMC-deficient patients is likely to blarne
for the weight and pigmentation abnorrnalities. Hypocorticolism and hypoglycemia on the
other hand are thought to reflect ACTH insufficiency, a phenotype that has moreover been
documented separately in patients with an isolated deficiency of pituitary ACTH (26). Our
findings on Tpit, and its particular expression and role in ACTH-expressing corticotrophs
in mouse, led us to investigate whether mutations in the TRIT human gene should produce
an isolated deficiency of pituitary ACTH.
Two out of three analyzed cases of children bom with an isolated deficiency in
ACTH tumed up with mutations in the TFIT gene (127). In one case, a homozygous point
mutation was identified that introduces a premature translation termination codon in the
open reading frame of TPIT. As a result, the TPIT protein is either translated in a truncated
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form that is inactive, or more Ïikely the faulty transcript is eÏiminated by a surveillance
mechanism known as non-sense mediated mRNA decay (NMD) ($6). This chiid’s parents,
and one grandmother, were found to be heterozygotes for the mutation but free of the
ACTH deficiency, making inheritance recessive. The second child studied was found to be
heterozygous for a point mutation that changes serine residue 12$, a residue conserved in
the T-box of ail known famiiy members, to phenylalanine. The ensuing mutant TPIT
protein in this heterozygote patient might be acting in a dominant negative mairner to
inhibit normal TPIT function coming from the TFJT allele that is not mutated.
1.3.3.4 Growth Signaling Factors
How the activities of Pitx, NeuroD I and Tpit transcription factors are regulated by
outside growth signaling factors is stiii misunderstood. Signaling factors intrinsicaily
expressed in Rathke’s pouch have been shown to suffice for corticotroph ce!! specification
from e9.5 and on (67,244). Prior to this, Shh signais seem to be required either for
induction or maintenance of ACTH expression, which is lacking in Fitx]-Hip transgenic
mice (245). No other gene deieted or mutant animais for pituitary restricted signaling or
transcription factors have shown a compiete absence of POMC/ACTH expression. The
early arrest of pituitary development caused by the absence of such pleiotropic molecules
as Bmps and Fgfs, or the possible incomplete penetrance of transgenic experirnentai
methods render the in vivo study of the specific roies of signaling factors in the
differentiation of POMC-expressing corticotrophs and melanotophs difficult. My Master’s
project stems from contradictory resuits that had previously been obtained by two groups of
investigators in their attempt to define the role of Bmp-4 signaling on embryonic
corticotroph specification. Indeed, ACTH expression was downregulated in ex vivo e9.5
Rathke’s poucli expiants cultured with Bmp-coated beads (67), whiie ACTH expression did
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flot appear to be affected in gain-of-function aGSU-BMP4 transgenic embryos (244). By
means of the extensive characterization of the rat POMC gene promoter in Dr. Drouin’s
laboratory and given that POMC expression is a marker of corticotroph ceils in the anterior
pituitary, my approach in elucidating the contribution of Bmp factors to corticotroph celi
differentiation has consisted in studying the role that Bmp signaling plays in the control of
FOMC promoter activity.
1.4 POMC Transcription
POMC promoter studies in our laboratory have been executed in the mouse
POMC/ACTH-expressing AtT-20 celi une, which has its origins in pituitary turnorigenic
tissues (24). Seeing that these ceils express such early protein rnarkers as NeuroDi, Pitx
and Tpit, AtT-20 celis are used as a model of differentiating corticotrophs (127,128,199).
The same rnechanisrns driving POMC promoter activity in AtT-20 cells would hence be
expected to induce POMC expression in corticotrophs, but not necesarily in rnelanotrophs
which seem to differ. NeuroDi for example is not expressed in melanotrophs (199).
POMC promoter studies in our laboratory have typically lcd to supporting in vivo evidence
in mouse models, and hence constitute an important tool to study the molecular basis of
corticotroph differentiation.
1.4.1 Corticotroph-Specfflc Regulation of PO1’IC Expression
1.4.1.1 POMC Promoter
FOMC promoter sequences from —480 to +63 bp were shown to have corticotroph
specific activity in AtT-20 ceils, as well as in transgenic mice (141,249). The —4801+63 bp
promoter, hereafier referred to as the full length promoter, was only expressed in transgenic
anterior and intermediate pituitary but not in hypothalamic regions also known to express
POMC. Other regulatory sequences would be involved in hypothalamic expression of
POMC (272). Deletion studies that made use of different regions of the pituitary-specific
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FOMC promoter, fused either alone or in different combinations to the lucijerase (tue)
reporter gene and transfected into AtT-20 celis, were performed to determine the
contribution to promoter activity made by the distal (-480/-324), central (-323/-166) and
proximal regions (-165/-34) (241). In doing so, the distal together with the central dornains
of the promoter were demonstrated to confer specificity to FOMC prornoter activity. Out
of the three latter regions, only the central one was shown to possess some activity on its
own.
Through footprint and mutation analyses, it was shown that individual regulatory
elements within the FOMC promoter contribute to its transcriptional activity (241). Indeed,
the loss of any of these elements decreased POMC prornoter activity significantly. Among
the many transcription factors that have been identified to mediate transcriptional control of
POMC at such binding sites (figure 1.5), only a few have been retained as having
corticotroph-specific roles. Namely, the bHLH factor NeuroDi acting in the distal region,
and the homeodomain-containing transcription factor Pitx 1 with its obligate T-box partner,
Tpit, both acting in the central region ofthe promoter. Not only would these two regulatory
elements, namely the distal NeuroDi Ebox (EbOXneuo) and central Pitx/Tpit binding sites,
be responsible for corticotropli specificity but they would moreover be mediating
transcriptional synergy between the distal and central domains ofthe FOMC promoter.
1.4.1.2 NeuroDi and Pitx Synergistic Interactions
Analysis of the regulatory elements contributing to AtT-20 cell-specific
transcription within the central domain of the POMC promoter led to the cloning of the
homeobox transcription factor Pitxl (Ptxl) (12$). Drosophilct bicoid-related Pitxl is a
member of a subfamily that also includes mammalian Pitx2, Pitx3, Otxl, Otx2, and
goosecoid (60). The Pitx subfamily of transcription factors is characterized by a paired-like
DNA-binding homeodomain in which residue 50 is a lysine. Pitx factors bind as monomers
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to a single site in the POMC promoter, where they act as transcriptional activators tbrough
their C-terminal transactivation domain (128). Besides its pituitary actions, Pitxl has also
been implicated in POMC expression in human small ceil lung carcinomas (SCLC) (180).
Pitx factors have been shown to be the basis for synergistic activities between thc
distal and central domains of the FOMC promoter (Figure 1.5), Pitx bound to the central
domain interacting with NeuroD I -containing 5HLH heterodimers bound to the distal
domain (198,199,242). NeuroDl, and related tissue-specific bHLH factors like MyoD in
muscle, dimerize through their HLH motif with ubiquitously expressed bHLH factors E12
and E47 (72). Only in the heterorneric form may NeuroDi, through its basic motif bind to
EbOXneuro and moreover collaborate with Pitx factors. ftideed, in vitro binding as well as in
vivo co-immunoprecipitation and transfection studies have shown that it is the ubiquitous
bHLH partner ofNeuroDl that directly interacts with Pitx factors (19$).
In the context of the full length promoter, both Pitx and NeuroD 1 binding sites are
required for transcriptional synergism (198). In transfection assays however,
transcriptional synergism can be reconstituted in the absence ofPitxl DNA binding activity
but not independently of DNA binding by bHLH factors, highlighting the importance of
protein:protein interaction for synergism (19$). Deletion ofthe distal domain resuÏted in a
thousand-fold loss of POMC prornoter activity in transgenic mice (198), and mutation of
Eboxueuro significantly compromised the activity of the full length FOMC prornoter in
transfected AtT-20 ceils (199). Although the Eboxneuro binding site for NeuroDi bHLH
transcription factors seems to be at the foundations of corticotroph-specific synergistic
activation of the POMC promoter, NeuroD 1 itself is flot required sensu strictu for FOMC
transcriptional activation. Indeed, substituting the Eboxneuro for an Ebox that binds
ubiquitous bHLH homodimers (Eboxb) restored promoter activity (199). $till, the
EbOXneuro ofthe distal region of the POMC prornoter is incapable ofbinding ubiquitous
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bHLH hornodimers, hence the requirement for NeuroDi in corticotrophs for sequence
specific recognition and activation of the EbOXneuro.
1.4.1.3 Tpit, an Obligate Partner of Pitx Factors
Pitx activity on the central domain of the POIiC promoter is dependent on
synergistic interactions with Tpit. from a mutational analysis of the regulatory elements
surrounding the Pitx binding site, Tpit was recently cloned in our laboratory as an obligate
Pitx partner (127). The Tpit binding site in the POMC promoter actually conesponds to a
haif site of the palindrornic Brachyury (T)-binding element (170). Tpit activity on POMC
can actually be replaced by T, to which it is the most reiated, but not by Tbxl which is
another T-box factor that is expressed in AtT-20 celis (127).
Pitx and Tpit can each weakly activate POMC transcription through their
respective binding sites, which are 5 bp away fiom each other. Together, they collaborate
in a synergistic interaction that would originate from their ability to cooperativeiy bind
DNA, as was evidenced in in vitro binding studies (127). The loss of either binding site
obliterates the synergistic activity between Pitx and Tpit. Protein:protein interactions
between Pitx 1 and Tpit factors are thought to be mediated by the Pitx 1 horneodomain.
Synergistic interactions between T-box factors and Pitx family members has been shown in
celi culture for Pitxl, Pitx2 and Pitx3, but flot for the ciosely related subfamily of Otx
transcription factors (127).
1.4.2 Hormonal Regulation of POMC Expression
Once the terminal differentiation of corticotrophs is cornpleted, the regulation of
FOMC expression mainly falis under a balance of stimulatory signais such as hypothalamic
corticotropin-releasing-hormone (CRH) and negative feedback signais such as
glucocorticoids (Gc) from the adrenal gland (Figure 1.6). These two modes ofregulation
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converge in corticotrophs to mainly control the secretion of pre-stored ACTH hormone in
an immediate response, or in a long-tenn response to adjust the transcription rate of the
FOMC gene.
1.4.2.1 CR11
The biological actions of CRH are mediated through the G-protein coupÏed
transmembrane CRI-I receptor (193). Receptor activation subsequently turns on the
adenylate cyclase second messenger system, leading to the production of cyclic AMP
(cAMP) and activation of cAMP-dependent protein kinase A (PKA). PKÀ is known to
control cellular functions through the phosphorylation of such transcription modulators as
the cAMP response element binding protein (CREB), cAMP response element modulator
(CREM), activation transcription factor (ATF)1/2 and general coactivators CBP/p300
(166). No such regulatory eÏements are present with the —4$0/+63 FOMC prornoter, yet
CRH stimulation ofAtT-20 ceils does resuit in the increase of FOMC transcription (70,71).
These CRI-1 effects are mimicked by cAMP analogs or by forskolin, and do flot appear to
require de novo protein syrithesis since POMC levels increase even in the presence of
cyclohexamide, an inhibitor of translation.
Several pituitary-specific POMC promoter sequences have been implicated in CRH
responses (8,15,102,136), but flot much is known of their mechanism of action. We and
others have shown that CRH inductive regulation of POMC expression in AtT-20
corticotroph ceils seerns to be the function ofprornoter regulatory elements for members of
the Nur77 subfamily of orphan nuclear receptors (154,172,194). Ibis subfamily of
transcription factors includes Nur77, also known as NGFI-B (164), Nur-related factor 1
(Nurrl) (131)and neuron-derived orphan receptor 1 (NOR-1) (186). Evidence that Nur77-
reÏated activity is the principal mediator of CRH inductive effects on POMC comes from
experirnents wherein the overexpression of a dominant negative Nur77 mutant blocks both
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CRH and forskolin actions (194). The binding site for Nur77 subfamily members is located
in the distal region (-395bp) of the FOMC promoter (194). This Nur response element
(NurRE) is a palindrome that binds Nur factor homodimers and heterodimers (154). The
two half sites share a partial homology with the monomeric Nur-binding response element
(NBRE) first characterized in yeast (256). Such a NBRE is moreover found in the proximal
region (-63bp) of the POMC promoter, but as the NurRE has been shown to be much more
responsive to CRH treatments, corticotroph-specific CRH actions on the POMC prornoter
would appear to be primarily mediated through the NurRE rather than the NBRE.
Unfortunately, functional redundancy between members of the Nur subfamily have
interferred with in vivo analysis, through gene deletion teclmiques, of their individual
pituitary or hypothalamo-pituitary functions (38,43). (38)
1.4.2.2 GR
Glucocorticoid (Gc) negative regulation of ACTH release and FOMC transcription
has emerged as a concept of feedback regulation operating to adjust activity of the
hypothalamo-pituitary-adrenal (HPA) axis with physiological homeostasis. Gc acts at two
levels in the HPA, basicalÏy on CRH neurons in the hypothalamus and on corticotrophs in
the pituitary. Gc effects are mediated through the glucocorticoid receptor (GR) (155). To
date, two different mechanisms have been proposed to account for GR-mediated repression
of POMC prornoter activity. Whether one or both of these mechanisms interfere with
FOMC expression during development, HPA homeostasis or pathology is not well
understood.
In one case, GR would mediate Gc-induced repression of POMC through direct
DNA contacts with a negative Gc response element (nGRE) located in the proximal domain
of the promoter (63). Deletion analysis has dernonstrated that the nGRE is required for Gc
repression of POMC in AtT-20 cells (63,173) and in transgenic mice (79,249). In vitro,
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three molecules of GR bind to the nGRE (61); however, the exact molecular basis of
transcriptional repression by the GR complex at this site is stili elusive. In vivo
experiments are moreover in support of a nGRE-mediated mechanisrn for GR repression of
POMC expression. GR-deficient mice are characterized by an upregulation of CRH and
POMC at both levels in the HPA axis (37). Mice that express, using knock-in technologies,
a mutant GR deficient in dimerization do flot exhibit the same phenotype. GR molecules
that no longer dimerize would stili be able to participate in transrepression mechanisrns of
gene control, but flot in GRE/nGRE binding. Mice expressing this forrn of GR showed
upregulated POMC expression in the pituitary, while their CRH levels in the hypothalamus
were under negative control presumably by monomers of GR (205). GR dimerization
hence seems to be required for the negative regulation of pituitary POMC levels.
Nevertheless, other mutant mice models are in support of alternative mechanisms of
negative Gc feedback on the FOMC promoter (168,169).
Centered at —63bp, the nGRE overlaps with the NERE, which suggests that GR
may likewise participate in a competitive mode of action to interfere with CRH/Nur
mediated activation of the POMC promoter. However, through AtT-20 transfection
experiments, the distal NurRE appeared to be a target for GR. Using lue reporters
containing three copies of the NurRE, GR was shown to be able to block Nur-dependent
activity (195). Direct protein interactions between GR and Nur77 are possible in vivo
(156), suggesting that the mechanism of GR transrepression of FOMC would be one that is
similar to the one characterized between AP-1 and GR on the collagenase gene promoter.
Control of transcription on this latter promoter, which is devoid of GR-binding sites,
appears to rest on antagonistic protein:protein interactions between AP-1 activators and GR
(10,103,269).
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1.4.3 Growth Factor Regulation ofPOMC Expression
1.4.3.1 LIF
Leukemia Inhibitory Factor (LIF) is a member of the interleukin (IL)-6 family of
cytokines and is expressed in normal fetal and aduit corticotrophs, as well as in ACTH
secreting adenomas (1). In vivo, LW has been shown to favor the differentiation of the
POMC-expressing celis at the expense of other pituitary celis. That is, the pituitary glands
of aGSU-LIF transgenic mice exhibited a hyperpiasia of ACTH-expressing ceils, which
accounted for 65% ofthe population of anterior pituitary ceils in comparison to 13% in the
wild-type (270). Although a potential role in the development and maintenance of
corticotroph ceil biology is suggested by these resuits, an understanding of the precise
actions of LfF on either proliferation or differentiation processes in the pituitary is lacking.
While LJF has been attributed a role in the regulation of corticotropli differentiation in the
pituitary, it has also been shown to inhibit proliferation of AtT-20 ceils (227). LTF does not
seem to be required for the establishment of the corticotroph celi lineage seeing that the
pituitaries of LIF knockout mice exhibit reduced, but stiil easily detectable POMC mRNA
levels (34).
In the context ofPOMC promoter activity, LIT has been demonstrated to enhance
CRH effects (204). LIF signaling is mediated by STAT transcription factors, and in
particular by STAT3 in pituitary celis. A few LIF/STAT3 response elements have been
identified on the POMC promoter (19), including one that overlaps the NurRE (20). Not
much more is known of the LTT-induced STAT3 mechanisrn of action on the POMC
promoter.
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1.4.3.2 IGF-
Studies had previously looked at the direct modulation of FOMC expression by
Transforming growth factor (Tgf)-t3 and Activin members of the Tgf- superfamily.
Activin-A has been reported to suppress basal ACTH secretion and POMC mRNA
accumulation from AtT-20 cells (14). Activins were initially isolated and characterized
based on their ability to prornote fSH secretion from pituitary gonadotropes (139). In
Bilezikjian’s work, recombinant (r) human Activin-A (13Af3A) treatments ofAtT-20 ceils for
4$ lus were shown to suppress ACTH secretion and POMC rnRNA expression by about
50%; this same treatment was however shown to inhibit by 25% the growth rate of AtT-20
cells (14). While the latter study reported that rTgf-f31 had no effect on POMC transcript
levels in AtT-20 ceils; more recent work suggests otherwise (1$). Tgf-13 is secreted by
hypothalamic astrocytes and the presence of TgfR-I receptors transcripts in POMC
expressing neurons had suggested that Tgf-J3 might 5e implicated in the modulation of
POMC neuronal activity. Indeed, rTgf-f31 treatrnents of mediobasal hypothalamic
fragments lead to an average 50% decrease of POMC mRNA levels detected by in situ
hybridization (1$).
A relationship between members of the Tgf-3 superfamiÏy of signaling molecules
and FOMC expression had already been established in the aforernentioned studies. The
basis of this reîationship seems to rest on negative modulation of POMC expression by
members of the Tgf-3 family. Whether Bmp regulatory pathways also lead to the decline
ofPOMC expression lias yet to be determined.
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1.5 Bmp Signaling
1.5.1 Tgf-3 Superfamily Functïons in Embryos
Bmps are a subfamily ofthe large Tgf- superfarnily ofpolypeptide growth factors
characterized by three conserved pairs of disulfide bonds and that moreover includes Tgf
r3s, Activins, hihibins, Growth differentiation factors (GDfs) Nodals and Mullerian
inhibiting substance or MIS (158). TgfJ3-related factors are secreted factors that mediate a
diverse set of cellular responses in species ranging from worms to mammals. Contributing
to our current knowledge of the developmental aspects of Tgf-3 signaling are three general
types of genetic experiments: genetic loss-of-function experirnents in Drosophila, ectopic
expression (mRNA injection into embryos or factor addition to tissues) in Xenopus, and
genetic loss of function in mice by homologous recombination. Through such work, the
Bmp homologue Decapentaplegic (Dpp) in Drosophila, initially identified as a dorsalizing
agent, has been shown to mediate among other developrnental events the dorsoventral
patteming of the embryonic ectoderm and midgut morphogenesis (113). Xenopus Brnp2/4
and Activin have been implicated in the formation of ventral and dorsal rnesoderm,
respectively (45,77); whule mammalian Activin and Tgf-3 have been found to be
modulators of ceil-cycle arrest, adhesion, and death (213). Bmp factors have been
designated as regulators of embryonal celÏ specification and morphogenic processes, such
as bone formation for which they were first identified (87).
The basic Tgf- signaling system involves ligand-induced assembly of a
transmembrane receptor complex, direct activation of Smad receptor substrates, nuclear
translocation and formation of a Srnad muÏtisubunit tra;;scriptional complex (Figure 1.7).
An important way in which diversity is achieved in Tgf- responses is through specific
ligand-receptor and receptor-Smad interactions.
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Figure 1.7 TGF-13 Superfamily Signalling Pathways
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1.5.2 Ligand and Receptor Families
Ail Tgf]3-related ligands are synthesized as inactive precursors that are
proteolytically activated by cleavage to yield mature C-terminal peptides that subsequently
assemble into dimers. This processing event is thought to occur within the trans-Golgi
network and would regulate the rate of Tgf-3 peptide secretion and hence signal production
during embryonic development. Subtilisin-like proprotein convertases (SPCs) have been
implicated in the latter maturation process. The function of these SPCs has been evaluated
in vivo and determined to be essential for Tgf- activity since SPC-deficient mice
(39,209)develop defects as severe as the ones observed in mice deficient in ligand, receptor
or Smad constituents ofthe Tgf-3 signaling pathway.
Tgf-3 ligands bind to two different types, termed typel and II, of ceil membrane
receptors with intrinsic serine/threonine kinase activity. Ligand binding experirnents
suggest that the receptor complex is a heterotetramer of two type I and type II molecules
(190). The type I receptor is inactive because a wedge-shaped GS (glycine-serine rich)
region is inserted into the kinase domain, disrupting the catalytic center (92). This GS
region is subject to phosphorylation by the ligand-activated typeil receptor, which is itself
constitutively active but requires ligand binding to trigger receptor complex formation and
activation of receptor kinase I (7). In the activated receptor complex, it is the type I
receptor that is the primary transducer for specific intracellular responses. Mutating GS
domain serines and threonines arrests both phosphorylation and signal propagation (7).
Mutations within the GS domain can also lead to the constitutive activation of type I
receptors. Replacing glutamine (Q) residues 233 in the type I Activin-like kinase (Alk)-3
receptor (BmpR-IÀ) and 203 in Alk-6 (BmpR-IB) by an aspartic acid residue generates
constitutively activated Alk-3 (Q223D) and Alk-6 (Q203D), which activate the Bmp
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specific signaling pathway in a ligand-independent fashion (2). In general, TgfJ3-reÏated
iigands are thought to first bind to type II receptors to then recruit type I receptors (Figure
1.7). However, Bmp ligand binding ability does flot appear to be restricted to receptor type
and impiicates a cooperative model (Figure 1.8) of receptor interactions with Bmp iigands
(87,145). Bmps can directly bind to type I receptors overexpressed in COS ceils (239), but
require type II receptor phosphorylation for activation of the signaling pathway. The latter
requirement can be bypassed through the overexpression of constitutivety active fonns of
Bmp-specific type I receptors Alk-3 (Q223D) and Alk-6 (Q203D), which exert Bmp effects
even in the absence of ligand stimulation and type II receptors (2,238).
1.5.3 Smad Sïgnaling
The first mediator of Tgf-13 signais to be characterized was the DrosophiÏa
Mothers Against Decapentapiegic (Mad) protein, identified in a genetic screen for genes
required to maximize Dpp signaling (124,203). Mad homologues Srna-2, Srna-3 and Srna
4 were then identified in C. elegans (215), while the first reported vertebrate homologue
was the tumor supressor DPC4/Smad4 (78). The general tenn Srnad, derived from Mad
and Sma, has been adopted to designate members of this famiiy of proteins which can be
classified into three groups according to structural and functional similarities. That is;
receptor-regulated Smads (R-Smads) Smadl, -2, -3, -5, and -8 invoived in ligand-specific
signaling; co-mediator Smads (Co-Smads) Smad4 and Smad4Ç3 participating in signaling by
diverse Tgf-f3 famiiy members; and inhibitory Smads (I-Srnads) Smad 6 and Srnad7 that
negativeiy regulate these pathways by preventing R-Smad phosphoryiation or formation of
R-/Co-Srnad functional complexes (36).
Smad proteins are the only known intraceiiular mediators of Tgf-f3 responses with
an estabiished capacity to transmit signal directly from the ceil membrane into the nticleus.
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Overexpression of R-Smads with Co-Smads in celi culture systems rnirnicks Tgf-j3 effects,
which are counteracted by specific Srnad signaling inhibitors ($5). Be that as it may, Bmp
signaling lias also been shown to take cffect in a Smad-independent fashion. The TgfJ3-
mediated decrease in IGFBP-5 transcript and protein syrnthesis, ultimately resulting in a
bÏock of muscle differentiation, are thought to implicate the c-Jun N-terrninalinal kinase
(JNK) signaling pathway rather than the Smad pathway (210). Inhibitors of MAP
(Mitogen-activated protein) kinase kinase-4 (MKK4), an upstream JNK activator, but flot
of Smad signaling blocked Tgf- effects on IGRBF-5 expression. It is however unlikely
that JNK is the primary mediator of Tgf-J3 signais seeing that the JNK-kinase takes several
hours to respond. The activity of a particular member of the Extracellular signal-regulated
kinase (Erk) subfarnily of MAPKK kinases (MAPKKKs), known as TGff3-activated kinase
I (TAK1), had been shown to be rapidly increased by Tgf- and Bmp-4 (267). The
indispensable role that Bmp factors seem to have in cardiomyocyte differentiation for
example, as inducers of cardiac transcription factors, appears to be rnediated by TAK1
(167). Tgf-3 activation of TAXi lias been described to occur through Bmp receptors as
well as the upstream reguiator TAB1 (TAK1 binding protein) (266). TAK1 in tum has
been shown to stirnulate the stress activated kinase p38 pathway, which subsequently
induces the nuclear activity of Activating transcription factor 2 (ATF2) (80). Smad and the
TAK1/p38 pathways were moreover found to act together in synergistically enhancing the
activity of the ATF-2 (214). Such work undelines the important role that Srnad
independent pathways play as mediators of Tgf-3 signaiing.
1.5.3.1 Smad Structure
Smad proteins (figure 1.9), about 400-500 amino acids in length, are made up of
two highly conserved N-terminal and C-terminal domains of giobular structure, separated
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by a more variable proline-rich linker (222,223). The N-terminal or Mad Homology-1
(MH1) domain typicalÏy corresponds to the DNA-binding domain of Smads (223). Once
recruited to DNA, Smads can independently regulate transcriptional processes through their
MH2 C-terminal (C-terminal) transactivation domain. Indeed, a construct composed of the
Smad MH2 domain fused to the heterologous GAL4 DNA-binding domain was able to
transactivate transcription of a reporter construct containing a GAL4-binding site (143). A
construct containing full length Smad was however inactive in this assay. This speaks of
the tight regulation of MH2 transactivating capacity by the MH 1 (transactivation repressor)
domain in the absence of ligand. The MH2 domain furthermore functions in receptor
interactions, $mad oligomer formation, and negative regulation of MH1 DNA-binding
activity (161).
1.5.3.2 Specificity in Recruitment and Acfivatïon ofR-Smads by Receptor/Ligand
Complexes
In the absence of ligand stimulation, R-Smads as well as Co-smads are mainly
found in the cytoplasm as oligomers in a closed conformation. Upon ligand-induced TgfJ3-
receptor complex formation, cytoplasmic R-Smads are recruited and phosphorylated by
activated type I receptors thereby alleviating the mutually inhibitory interactions between
the MH1 and MH2 domains (161). Receptor phosphorylation of R-Smads occurs in a
ligand-specific manner on a serine-rich SSXS motif found exclusively in the C-terminal
domain ofR-Smads (120): thus, the Tgf-f3 and Activin type I receptors activate Smad2 and
Smad3, whereas the Bmp type I receptors target Smadl,-5, and -8. Smad-receptor
interactions are prompted by a basic pocket in the C-terminal domain of R-Smads that
docks to the phosphorylated GS receptor region. Specificity in the latter interaction is
mediated by loop 3 and a-helix 1 (aH-l) ofR-Smads (Figure 1.9) and loop 45 ofthe type I
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receptor kinase (158). Activated R-Smads then dissociate from the receptor and assemble
into complexes with Co-Smad4, subsequently transiocating into the nucicus where they
either activate or repress gene transcription in collaboration with specific DNA-binding and
co-regulator proteins.
1.5.3.3 R-SmadlCo-Smad Complex Formation and Transiocation into the Nucleus
Transcriptional activity of R-Smads requires the participation of Smad4 in the
activated Srnad nuclear complex, as dernonstratcd for Ga14-Smadl and -Srnad2 fusion
proteins in Smad4-deficient celis (144). Stnicturally, Srnad4 is very simila;- to R-Smads
minus the C-terminal phosphorylation SSXS motif (15$). Smad4 was identified as the
tumor supressor product ofthe deleted in pancreatic carcinoma (DPC) locus 4 (5$); (126),
mutated in nearly haif of pancreatic cancers (216). The requirement for Smad4 in Tgf-3
signaling is suggested by its partnership with TgfÏ3-, as well as Activin- and Bmp-activated
R-Smads (126,276,277). Interactions between R- and Co-Srnads are mediated by
respective MH2 domains; Smad-mediated transcription is suppressed by Smad4 MH2
mutations disnipting Smad hetero-oligomerization (161). Smad4 is not required for nuclear
transiocation of the Smad complex, nor for the association of R-Smads with DNA-binding
partners. Rather, Smad4 promotes binding to DNA and stability to the transcriptional
Smad complex through its MHldomain, while its MH2 domain provides Smad4 with the
capacity to act as a transcription co-activator ($2). Smad transcriptional activity is
abrogated in Smad4-defective cells (144). In vivo, interactions between Smad and general
co-activators on promoters actually requires intact Smad4 activity, as is the case for
efficient co-activation of Srnad3 by CREB-binding protein (CBP) (6$).
Tgf-mediated regulation of gene responses depends on the transiocation of the
activated Srnad complex to the nucleus. One set of data suggests that this nuclear import
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mechanisrn would rely on a basic nuclear localization sequence (NLS)-like motif located in
the MHÏ domain of R-Smads. Mutating this motif in $mad3 eliminated its TgfJ3-induced
capacity for nuclear transiocation, without interfering with its ligand-induced
phosphorylation, DNA-binding activity or heteroligomeric association with Smad4 (208).
Another mechanism which diverges from the classical NLS-directed nuclear transiocation
impÏicates a ligand-independent activity found in the MH2 domain of Smad2 in particular
(262).
1.5.4 Smads as Transcription Factors
Smad proteins fulfiul their role as direct mediators ofTgf- gene responses through
their sequence-specific DNA binding and transactivation or transrepression activities.
Smad recruitment to DNA is essential for Smad control of transcription. The Smad MH2
domain, when fused to the heterologous GAL4 DNA-binding domain, was able to activate
transcription of a reporter construct containing a GAL4-binding site (143). Smad proteins
therefore possess an intrinsic transactivating activity that is present in their MH2 domain
and that is independent of any other protein collaboration, but requires Smad binding to
DNA.
1.5.4.1 Smad Binding to DNA
There are currently two prevailing views regarding the tethering of Srnad proteins
to target gene promoters. One view is that Smad proteins regulate transcriptional processes
by directly binding to DNA. Both R-Smads and Co-Smads can bind DNA through a f3-
hairpin motif in their MH1 domain (figure 1.9). The DNA-binding activity of the MH1
domain is under negative control by the MH2 domain in the absence of ligand, the latter
mechanisrn contributing to Smad inactivation in the absence of ligand. Cornmonly
accepted as a Smad-binding element (SBE) or Smad box is the 5’-AGAC-3’ sequence
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found in one or multiple copies in such TGf-f3/Smad-responsive promoters as those of the
c-fun, collagenase I, Iminunogtobulin-A (IgA,) and Plasminogen activation inhibitor (PAl
1) genes (55,90,192,275). Oligonucleotide selection experiments using recombinant
Smad3 and Smad4 (273) had originally identified an 2bp 5’-GTCTAGAC-3’ sequence as a
putative SBE. Direct binding of the Srnad3 MH1 domain to this sequence has been
characterized through crystallographic analysis (223). Smad3 was shown to bind each haif
of the palindromic SBE through an 1 1-arnino acid 13-hairpin that established contacts with
the 5’-AGAC-3’ sequence in the major groove of the DNA. GC-rich sequences with a 5’-
GCCGnCG-3’ consensus motif as found in the tinnzan promoter (263) have been
dernonstrated to interact directly with Drosophila Smadl-related Mad. Srnads have been
shown to be able to activate Tgf-J3 inducible transcription from certain promoters in the
absence of other transcription factors (275), but DNA-binding properties of Smads
considered, it is very unÏikely that Tgf-13 responses can be mediated solely by SBEs.
Indeed, in vitro Smadl, Smad3 and Smad4 can bind equally well to the SBE (223). That is
flot surprising considering that the sequences that make up the DNA binding j3-hairpin of
the three Smad proteins are the same. The 3-hairpin loop of Smad2 on the other hand bears
an extra 30 amino acids that interfere with its DNA binding activity (223). In addition to
the apparent lack of DNA binding specificity, there is the question of low binding affinity
ofSmad proteins which has been estimated to be 2.6-4.9 X i07 M (223). Greater affinity is
obtained by multiple copies ofthe SBE, which have been found in the PAl-1 promoter (52)
for example.
Compelling evidence supports the view that Srnad heterodirners associate to
promoter sequences through protein:protein interactions with specific DNA-binding
partners, allowing for greater affinity and specificity in Tgf-3 responses. The most
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common spiice variant of Smad2 actually lacks DNA-binding activity because of an arnino
acid insert located next to the f3-hairpin loop (223,265). Whether or not a particular $rnad
can bind to DNA, specificity in their recruitrnent to promoters wotild for the rnost part
occur through interations with DNA-binding partners. Efficient activation of the Xenopus
Yix.2 promoter for example (31) requires that Smad binding sites lie in close proximity to
binding sites for the winged lieux Forkhead activin signal transducer (FAST)-1
transcription factor, also known as FoxHl.
1.5.4.2 Tgf3-Responsive Genes
There are mariy examples of Smad cooperativity with DNA-binding partners in the
regulation of Tgf-3/Activin signaling pathways. The first natural Smad transcriptional
complex was described on the Xenopus homeobox Mix.2 gene, an irnmediate-early activin
response gene (31). fAST-1 was identified as the Smad2/4 DNA-binding partner in the
temary complex bound to the Activin response element (ARE) of the activated Mix.2 gene
(31). Smad2-FAST specific interactions have been shown to be rnediated by a-helix 2 (a
H2) of the Smad MH2 domain (32). The mouse homologue FAST-2 was soon after
implicated in mouse goosecoid (gsc) gene regulation by Activin (125). FAST-2
transactivation of the gsc prornoter requires Smad2 protein interactions and subsequent
Smad4 recruitment into a ternary complex. Smad2 activation of the gsc promoter was
shown to be antagonized by Smad3, which competes for DNA contacts with the Smad4
MH 1 domain (125). On 1 2-0-tetradecanoyl- 13 -acetate (TPA)-responsive gene promoter
elements (TREs), which were shown to mediate Tgf-3 transcriptional responses on such
genes as PAl-] and clusterin (101,107), Smad3 has the capacity to enhance the activity of
c-Jun at AP-1 binding sites. Such protein associations to TPA-containing TgfJ3-responsive
elements (TREs) depend on ligand- stimulated receptor activation, which correlates with
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the Smad complex marching into tue nucleus as a resuit of receptor
activationlphosphorylation.
Although physical interactions between Smads and binding partners have been
detected in almost ail cases, and would be at the basis of target gene selectivity, they do flot
seem to be required to carry out some Tgf- gene responses. Jndeed, no interactions
between the bHLH Transcription factor E3 (TFE3) and Smad3/4 proteins was shown (89)
yet ail three proteins interact with both PAl-1 and Smad7 prornoter sequences through a
TFE3 Ebox and a SBE found in proximity to each other.
Less is known of the mechanisms through which Tgf-f3 signaling pathways
directly inhibit gene transcription. Tgf- is a prominent inhibitor of skeletal muscle celi
differentiation (159,18$) that has recently been demonstrated to block the activity of MyoD
in initiating the myogenic program (142). Downstream of Tgf-3, Smad3 was shown to
repress the transcriptional activity of MyoD on Ebox motifs of the muscle creatine kinase
(MCK) promoter. By physically interacting with MyoD, Smad3 interferes with the
formation of MyoD/E protein dimers required for efficient activation of F-box regulatory
elements such as those found in the MCK enhancer. Although Smad3 has also been
implicated in the downregulation of androgen receptor- (84) and osteoblast transcription
factor CBFAY- (4) activated transcription, respective mechanisms of transcriptional
repression have yet to be elucidated.
1.5.4.3 Bmp-responsive genes
Transcriptionai responses to Bmp signais are less understood due to the smaller
number of Bmp target genes identified so far. Despite this, unique insights on Smad
function have been provided by the study of molecular mechanisms underlying Bmp
signaling pathways. Bmp/Smadl-mediated induction of osteopontin gene expression
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occurs through Smadl dispiacernent of horneodomain-containing Hoxc-8 in1ibitoiy
activity (221). In this case, direct interactions between Smadl and Hocx-8, which do flot
depend on Smad contacts with DNA, prevent Hoxc-8 repressor from binding to osteopontin
promoter elements. Bmp-mediated transcriptional activation lias moreover been shown to
occur through cooperative mechanisms similar to those characterized in TgfJ3/Activin
pathways, wlierein DNA binding sites for both Smad and partner proteins contribute to the
response. Bmp induction of Xvent2 expression requires both SBE and (Ornithine
decarboxylase antizyme) OAZ binding elements (83). Similar to the Smad2 partner FAST,
efficient binding of OAZ to the Bmp response element (BRE) in the mammalian Vent-2
promoter requires association with Smadl and an intact SBE (83). The iack of a consensus
Srnadl/5/8 DNA binding site renders the study of Bmp gene responses at the molecular
level ail the more difficuit. Smadl lias been demonstrated to act through a Mad-like GC
rich site to activate the Srnad6 gene (99,123) and through both Srnad box (AGAC) and Mad
consensus sites to induce Id expression (116). The Bmp consensus may perhaps be a
reflection of the cofactor involved.
There are also examples of Smads cooperating with DNA-binding partners in the
regulation of Drosophila Dpp-target genes. Dpp-dependent activation of Tinman
expression depends on the cooperativity of the Medea (Smad4 homologue)/Mad complex
with Tinman, which participates in its own autoregulation (263). for other genes, the Tgf
f3 pathway that mediates their transcription is not a direct one. Activation of vestigial (vg)
for example requires prior transcriptional downregulation of brinker (brk), coding a
homeodomain-containing repressor of Dpp target genes that acts by binding to Mad sites
(114,157,211). Repression of brk is mediated by Mad and the zinc finger Mad cofactor
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Schnurri (Sim). In the end, expression of vg is determined by competitive positive and
negative Mad and Brk signais, respectively.
1.5.4.4 Co-Actïvators and Co-Repressors
R-Smad and Co-Smad recruitment of general co-activators, such as p300 and
Creb-binding protein (CBP) (68,200) has been implicated in Smad-mediated transcriptional
activation (68). Through their ability to position histone acetyi transferases (HATs) near
nucleosomes and hence remodel chromatin, or to interact with components of the general
transcriptionaÏ machinery, co-activators such as p300 and CBP increase transcription of
their target genes (253). Meianocyte-specific gene (MSG1), an orphan transcriptional
activator with strong transactivating activity but lacking DNA binding activity, associates
with Smad4 and contributes to Srnad-rnediated transcription (161).
Cooperative effects between Smads and other transcription factors may occur at
the levei of co-activator recruitment. The cooperative signaling of Bmp-2 and the cytokine
LIF in astrocyte formation is mediated by a complex formed of Smadl and Stat3 proteins
that do flot interact directly, but are bridged by contacts with p300 (96). The vitamin D
receptor (VDR) has been shown to physically interact with Smad3 in transcriptional assays
and this interaction has been shown to involve steroid receptor co-activator (SCR)- 1,
another protein with associated HAT activity (268).
In some cases of genes repressed by Tgf-, downstream Smad proteins serve to
disrupt specific transcription factor associations with coactivators. Smad repression of the
c-inyc gene for exampie has been described to occur through a Transcription inlribitory
eiement (TIE)/Elongation factor 2 (E2F) binding element (264), to which both Smad3 and
E2F-4 bind. Tgf- induction leads to the binding of Smad3, without disrupting E2F-4
DNA tethering, and interferes with the recruitment of co-activators by E2F-4.
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The transcriptional shut down of other Tgf-3 target genes, such as that of
osteocatcin (21,182,196), transin/strometysin (110) and Cdc2SA (94), has been attributed to
Smad recruitment of histone deacetylase (HDAC) activity that is associated with such co
repressors as c-ski (3,231,232), $noN (228,232)and TG-interacting protein (TGIF) (258).
Co-repressor associations with DNA typically resuit in the deacetylation of chromatin and
the packing of nucleosome, hindering further transcriptional processes (47). SnoN and c
ski are two closely related members of the Ski family of nuclear proto-oncoproteins
recently associated with the negative control of TgfJ3-/Activin-induced gene responses,
although c-ski has also been shown to antagonize Bmp signaling (254). These two
repressors are thought to maintain Tgf-3/Activin target genes in a repressed state in the
absence of ligand and to participate in negative feedback control of Tgf-3 signaling
(228,232); in response to ligand activation, SnoN and c-ski would rapidly be degraded and
would hence allow target gene expression to proceed. c-ski, in addition to its HDAC
associated activity, lias been shown to repress transcription by competing with Smads for
co-activators.
Homeodomain transcriptional repressors of the TGIF farnily have been
demonstrated to negatively regulate transcriptional processes through their ability to
directly bind DNA (Bertolino E 1995; Yang Y 2000), and recently through interactions
with Smad2 as well as the pleiotropic Sin3 co-repressor complex to block Tgf-induced
gene expression (258,259) (163). Smad transcriptional activity can also be blocked by
binding of the zinc finger nuclear protein Ecotropic virus integration (Evi)-1 or adenoviral
oncoprotein E region lA (FiA), which interfere with Smad associations to co-activators
(53,18 1). Competition between Smads and lirnitng amounts of co-activators and co
repressors in a celi may determine the outcorne ofspecific genetic responses to Tgf-.
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1.5.5 Regutation ofthe TGf-f3 Signaling Pathway
Controlling the level of Tgf-/Smad signaling in a celi is believed to determine
the biological activity of the pathway. Regulators have been identified at several steps.
1.5.5.1 Ligand/Receptor Interactions
Positive regulators of the Tgf-3 ligand subfarnily, in particular, are betaglycan and
endoglin accessory proteins. Initially detected through ligand cross-liking methods (30),
betaglycan or endoglin have corne to be known as the type III Tgf-f3 receptors. These
membrane-anchored proteoglycans stabilize Tgf-f3 rnoÏecules in a conformation optimal for
binding to the signaling receptors and hence facilitate ligand interactions with type II
receptors. The extracellular component of type III receptors may also be released; in this
case, the soluble forrn of the receptor may antagonize Tgf-3 signaling by sequestering
ligand (147). The outcome of type III receptor regulation of Tgf-3 signaling appears to be
a ftinction of glycosaminoglycan modifications (66). The Tgf-3 receptor activition process
itself is maintained in check by immunophilin FKBP 12 binding to the GS domain of type I
receptors, which prevents the occurrence of ligand-independent receptor phosphoryÏation
(160). Phosphorylation actually activates the type I receptor by switching its GS region
from a FKBP12 inhibitor- to a Srnad substrate-binding site (93). The pseudoreceptor
BAMBI, which lacks an intracellular kinase domain, is another inhibitor of Tgfj3 type I
receptors that functions through the formation of inactive dirners with type I receptors
(189).
Various families of diffusible Tgf-f3 ligand-binding proteins have been
characterized in several species as negative regulators of respective signaling pathways.
Through ligand sequestration methods, these extracellular antagonists are thought to
function in vivo to further delineate the areas of Tgf-J3 activity in tissues. One such
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negative regulator of Tgf-3 activity is the N-terminal propeptide that is cleaved off of the
prohormone, but remains non-covalently bound to the secreted C-terminal mature Tgf-
molecule. 11e N-terminal propeptide, known as Latency-associated protein (Lap),
interferes with receptor recognition of the mature Tgf-3 peptide (226). The physiological
mechanism of latent Tgf-f3 activation remains undefined.
follistatin on the other hand is a soluble secretory polypeptide that specifically
blocks receptor recognition by Activin (51). Its contacts with Activin molecules are made
through a cysteine-rich protein module that is found in many growth factor binding
proteins. ht vivo evidence supporting a key role for follistatin in the regulation of Activin
mediated developmental processes cornes from null mice, which exhibit developmental
defects similar to those ofActivin-deficient mice (162).
Many proteins across several species have been characterized to form inhibitory
complexes with ligands of the Brnp family. Chordin and Noggin, initially identified for
their ability to counteract Bmp ventralizing activity in Xenopus, also exert their negative
control over mammalian Bmps in such processes as neuralization, bone and tooth
morphogenesis (74). Both specifically bind to Bmps, but not to Activin or Tgf-. The
DrosophHa Short gastrulation (sog) is a homologue of Chordin and blocks Dpp signaling
(13). The DAN family ofBmp antagonists has very recently been implicated in a variety of
developmental processes govemed by Bmp and Nodal factors, and includes: Xenopus
Cerberus (Cer); chick Caronte; as well as mammalian DAN, Dante, DrmlGremlin, Cer 1
and protein related to DAN and Cerberus (PRDC) (88,207,271).
There are also antagonists of the aforementioned antagonists shaping Tgf-13
responses. Tolloid, Xolloid, Twisted gastnilation (Tsg) and orthologues identified in flues,
amphibians and mammals are ail metalloproteases that interact and cleave BMP antagonists
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thereby releasing biologically active Dpp/Bmp (171). In vivo, these metalloproteases are
thought to counteract the activity of Tgf-13 antagonists and hence provide surrounding
tissues with high Dpp/Brnp signaling.
1.5.5.2 Smad Sïgnaling
1.5.5.2.1 R-Smad Availability
R-Smad availability to Tgf- receptors is regulated by Smad anchor for receptor
activation (SARA), which binds and escorts unphosphorylated R-Smads to the
transmembrane receptor kinase (250). R-Smad activation appears to depend on its
association with SARA since interfehng with Smad2-SARA interactions inhibited Smad2
signaling (261). Moreover sequestering R-Smads in the cytoplasm prior to receptor
activation is the microtubule network (56). Unphosphorylated Smad 2 associates with F3-
tubulin, a constituent of the microtubule network; activation of the signaling pathway
results in Smad2 dissociation from 3-tubulin. Microtubules are hence thought to impose a
negative regulation on Tgf-F3 signaling in the absence of ligand stimulation. Once signaling
is turned on, receptor access to microtubule-bound Smads would be facilitated by SARA.
1.5.5.2.2 Ubiquitin-Proteosome Ubïquitination
Actively controlling $mad turnover in Tgf-f3 cellular responses is the ubiquitin
proteasome pathway (260). Essentially, ubiquitin residues are first activated by an El
ubiquitin-activating enzyme, then transferred to a ubiquitin-conjugating (E2) enzyme and
attached to the substrate in the presence of an E3 ubiquitin ligase. The Smurf family of E3
ubiquitin ligases specifically regulates Smad activity (17,274,278). Smurfl preferentially
binds and inactivates Bmp-regulated $mads; overexpressed in Xenopus ernbryos, Srnurfl is
capable of antagonizing Bmp signais involved in pattem formation (27$). Smufr2 on the
other hand antagonizes Smad-2 dependent signais, recognizing Smad2 over Smad3 (17).
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Such interactions between Smurfs and Srnads are iigand-induced, and would hence be
implicated in a loop of negative feedback regulation. But then again, studies showing that
the ubiquitin-proteasome system is irnplicated in the degradation of co-repressor SnoN as a
resuit of Tgf-f3 signaling activation would argue that proteolysis aiiows signaling to begin
(228,232). Phophorylated Smad2 and Smad3, once translocated into the nucleus, have been
shown to induce proteolytic degradation of SnoN by coilaborating with the anaphase
promoting compiex (APC) (17). Another study suggests that a Smad2-Smurf2 ubiquitin
ligase compiex targets SnoN for degradation by the proteasorne (17). In Drosophila,
$murfl/2 homologue Dsmurf has been identified as an important negative regulator ofDpp
signaling in vivo (197).
1.5.5.2.3 Inhibitory Smads
Smad6 (95) and Smad7 (176) are Smad proteins that antagonize rather than
transduce Tgf-f3 signais. Although structuraiiy different from other members of the Smad
family, inhibitory Smads are evoiutionanly conserved; Smad6 and Srnad7 were also
identified in Xenopzts (176) and Daughters against Dpp (Dad) in Drosophila (251). Smad6
specifically blocks Bmp signaling pathways by competing with Smad4 for binding to
receptor-activated Smadl (81). Smad7 on the other hand acts as a negative regulator of
signais by Tgf-3, Activin as weII as Bmp. By interacting with activated type I receptors,
Smad7 interferes with the phosphorylation of R-Smads by a mechanism that implicates
ubiquitin-proteasome degradation (65). That is, Smad7 promotes the association of
ubiquitin ligases Smurfl and Smurf2 to Tgf-3 type I receptors and thereby induces their
turnover (65,106).
Transcription of Smad6 and Srnad7 is induced by the iignads they inhibit
(176,177)), suggesting that inhibitory Smads function in a feedback ioop to control the
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extent of the Tgf-(3 response. In developmental processes, signal regulation by inhibitory
Smads may serve to attenuate tissue sensitivity to Tgf-3 signais (177). Smad6 and Smad7
autoregulatory circuits appear to fine-tune Brnp-4 activities irnpÏicated in Xeitopzts
ectodermal patteming (177). Seeing that inhibitory Smads have different specificities for
Bmp and Tgf-3 signaling pathways, the relative strength of such distinct signaling
pathways could be deternined by $mad6 and $mad7 expression levels in a celi.
1.5.5.2.4 Crosstalk
In vivo, a ccli is likely to be simultaneously exposed to multiple cytokines. It
seems the case therefore that two or more signaling pathways couid be activated in one
same ccii, either participating in the synergistic or antagonistic control of gene responses.
Brnp and Activin factors of the Tgf-f3 superfamily have been shown to antagonize
themseives in specifying the ventraldorsal polarity of mesoderm in Xenopus; Brnp!Srnadl
signais ventralizing and Activinl$mad2 dorsalizing embryonic rnesoderrn (75). Inhibition
of Bmp signaling in early embryos resuits in ectopic forniation of dorsal rnesoderm,
suggesting that endogenous Bmp signais are able to antagonize Activin dorsalizing effects
in vivo (75). It has been suggested that the two Smad—mediated signaiing pathways might
cross-interfere througli competition for Smad4 (28). Both positive and negative MAPK
reguiation of Smad activity lias been documented. Epidermai growth factor (Ego
activation of MAPK or Erk, rnediated by the Ras pathway, wouid interfere with Smad
signaiing by phophorylating R-$rnads in the iinker region and in doing so inhibit Smad
nuciear translocation (118,119). Inhibitory crosstalk between Egf and Tgf- signaling
pathways lias moreover been demonstrated to occur at the ievei of TGTF Smad co-repressor
activity. Indeed, Egf signaling via the Ras-pathway can cause the phosphoryiation of
TGIF, leading to its stabiiization and favouring tlie formation of Smad-TGIF inhibitory
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complexes (146). Oncogenic Ras has moreover been shown to negatively modulate Tgf-f3
signaling by increasing the turnover of tumor supressor $mad4 (212); whereas ceils treated
with interleukin- Ï and interferon-y become resistant to Tgf-f3 growth inhibition effects
through the induction of Smad7 expression mediated by activated Nuclear factor kappa B
(NF-Kb) and Jun-activated kinase (Jak)/Stat-1, respectïvely (16,252).
Different signaling pathways have also been shown to converge to enhance Smad
mediated gene responses. Functional and physical interactions between Smad3/4 and c
Jun!c-fos suggest that Smad and MAPK!JNK signaling can converge at AP1-binding
promoter sites (275). Bmp-2 and LIF act in synergy to promote astrocyte deveÏopment
through transcriptional complexes containing Smadl and STAT3, bridged together by
p300. Many other Smad modulatory signaling pathways, positive and negative, have been
described (160) and wouÏd certainly account for the diversity in biological Tgf- responses.
1.5.5.3 Aberrant Regulation ofTgf- Signaling Leadïng to Cancer and Human
Diseases
In the last years, the interest in studying the extent to which Tgf-3 growth factors
exercise control over growth and differentiation during normal development stems from the
recognition that disregulation of these pathways can resuit in malignant transformation and
hurnan disorders. Tgf- is well known for its inhibitory effects on ceil proliferation,
through the induction of Gi anest or activation of celi death mechanisms for example
(213); loss of such a signal hence thought to predispose or cause cancer. Mutations in
genes encoding components of the Tgf- signaling pathway have been detected in different
forms of cancer (78,206). Tgf-3 type II receptor mutations have been found in
gastrointestinal cancer, as well as in colon or gastric tumors of individuals with hereditary
non-polyposis colon cancer (RNPCC) (149). Smad2 and Srnad4 have been shown to be
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inactivated in a significant portion of pancreatic and colon cancers (257). EÏevated levels
of Tgf-3 negative regulators can resuit in oncogenesis owing to their ability to render TgfJ3-
responsive ceils resistant to Tfg-f3 signais. Indeed, abnormally high expression of Ski and
SnoN has been detected in human tumors (69,184). Developmental processes are moreover
profoundly affected by physiologically abnormal levels of Smad signaling in a celi.
Individuals carrying a single mutant TGIf allele have been shown to suffer from
holoprosencephaly, the most common structural defect of the developing forebrain in
humans (76). In these patients, Nodal signaling pathways implicated in neural axis
formation are believed to be affected. Perturbations of the Tgf- superfamily may also lead
to bone and vascular diseases; mutations in the human BMFR-IJ gene have been shown to
be responsible for the pathogenesis of primary pulmonary hypertension (PPH), while
nnitations in endoglin and Al-l have been associated with the pathogenesis of hereditary
hemorrhagic telangiectasia (HHT) type I and type II, respectively (165).
It is through the identification of mutations within genes encoding components of
the Tgf- signaling pathway, and the study of genetic defects that are brought about by
such mutations that one may fully comprehend the many parameters of normal TgfT3-
mediated celi growth and development. In the mean time, one would hope to understand
the molecular basis of such genetic responses in more accessible but stili relevant systems
such as ceil culture to ultimately be able to correctly process the available genetic
information.
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CHAPTER2- PROJECT DESCRIPTION
Conflicting resuits in the litterature initialiy ied me to question the particular role
that Bmp signais, expressed in the developing pituitary during the period of cellular
differentiation, play in the deterrnination ofthe POMC-expressing corticotroph celi lineage.
As an initial step towards this question, my approach consisted in studying the regulation of
POMC expression by Bmp signaiing pathways in the AtT-20 corticotroph celi une. An
action of Bmp signaling on POMC transcription would constitute a strong argument in
favor of a roie of this pathway in ceil differentiation since expression of the POMC gene
constitutes the “raison d’être” of corticotrophs. The finding that Bmp signais repress
POMC expression and POMC prornoter activity is interesting in itself because no other
mammalian target gene has been reported to be negatively regulated by Bmps. Hence, I
proceeded to investigate the moiecular basis of this Bmp negative gene reguiation. The
role of Bmp-specific Alk receptors, Aik-3 and Aik-6, as weii as the role of the Smadl
signal transducer in POMC regulation was investigated. Specificity of Bmp action xvas
moreover an important issue in understanding the mechanisrn of Smad action on the POMC
promoter. With the understanding that specificity in Srnad transcriptional responses relies
on the ability of Smads to bind DNA at consensus sites and moreover make contacts with
distinct DNA-binding partners, I defined Smad interactions with POMC transcription
factors as well as with POMC promoter sequences. Cruciai to this course of study were
previous findings that activation of POMC transcription requires the combinatorial activity
of different trans-acting transcription factors, including NeuroD 1, Pitx, and Tpit.
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CHAPTER3- ARTICLE:
“Bmp (Smad)-Mediated Repression of POMC Transcription by Interference with
PitxlTpit Activity”
NUDI Maria, Jean-François Ouirnette and Jacques Drouin
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3.1 Summary
The mature anterior pituitary gland harbours six distinct hormone-producing celi
types. The emergence of these different ceil populations early on in development is
thought to depend on specific sets of transcription factors, the activity of which would be
coordinated by growth factors expressed within and around the developing pituitary.
Previous studies do not agree on the role Bone morphogenic proteins (Bmps) play in the
differentiation of corticotroph ceils, which are characterized by the expression of
proopiomelanocortin (POMC) prohormone and adrenocorticotropin hormone (ACTH). We
show that activation of Bmp signaling pathways in AtT-20 corticotroph celis, whether it be
through recombinant (r)Bmp-4 treatments and/or overexpression of constitutively activated
Alk-3/-6 receptors or Srnadl/4 intracellular mediators, downregulates POMC expression
and promoter activity. Overexpression of Srnad6 or Smad7 inhibitors counteracts these
negative Bmp effects. POMC prornoter activity relies on the corticotroph-specific
functions of Pitx, Tpit and NeuroD 1 transcription factors. We find that intact Pitx and Tpit
regulatory promoter elements are required for Bmp-rnediated repression ofFOMC activity.
In showing that Bmp signaling can directly interfere with synergistic interactions between
Pitxl and Tpit, and moreover that Smadl binds Pitxl and Tpit in vitro, we propose a Smad
mediated mechanism of POMC prornoter regulation by Bmp that directly targets Pitx
and/or Tpit.
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3.2 Introduction
Bone morphogenic protein (Bmp) factors belong to the Transfonning growth factor
f3 (Tgf-f3) superfamiiy of nutltifunctionai secretory peptides that regulate such diverse
celiular responses as celi migration, adhesion, proliferation, differentiation and death.
Recently, transgenic and gene-deleted mice experirnents have irnplicated Bmp-4 in the
initial inductive phase of pituitary morphogenesis. The pituitary develops out of a layer of
competent oral ectoderm, which upon contact with inducing neuroectoderrn or ventral
diencephaion folds into a stntcture known as Rathke’s pouch (RP). Bmp-4 is detected in
the ventral diencephalon directly overlying the pituitary primordium; abrogation of this
activity in Brnp-4 nuli (1) or Fitx]-Noggin transgenic mice (2) compromised initiation of
RP formation. Neuroectodermal Bmp-4 signais are gradually lost as ceilular proliferation
and differentiation events are initiated in the glandular pituitary structure derived from RP.
In paraïlel, Bmp-2 signais appear ventrally in the oral ectodenu as well as mesenchyme,
and together with dorsal fibrobiast growth factor (Fgf)-$ signais, they have been proposed
to establish pituitary celi fate-defining pattems of gene expression (2;3).
Six distinct hormone-producing ccli types arise in the developing pituitary:
corticotrophs, gonadotrophs, iactotrophs, somatotrophs and thyrotrophs within the anterior
lobe, and melanotrophs within the intermediate lobe (4). The emergence of these distinct
celi fates from a common primordium is coordinated by specific sets of transcription
factors expressed in a precise spatiotemporal mariner during pituitary organogenesis. The
expression and activities of these transcription factors are thouglit to be specified early on
by extracellular signaling molecules such as Bmp factors. In the case of gonadotroph
differentiation, Bmp-2 lias been shown to directiy induce the expression of the GATA-2
zinc finger transcriptionai activator of gonadotropli-specific luteinizing hormone (LII) and
Jollicle-stimulating hormone (fSH) gene expression (5). The roie that Bmp signaling might
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be playing in the establishement of corticotroph celi identity is presently unclear.
Corticotroph celis distinguish themselves from other anterior pituitary celis through their
expression ofproopiomelanocortin (POMC) and adrenocorticotrophin hormone (ACTH) by
e12.5, ACTH arising from the proteolytic maturation of POMC (6). ACTH expression in
RP expiants cultured in the presence of Bmp-2 expressing COS celis was significantly
downregulated (3); however, unaffected ACTH protein levels in the pituitaries of aGSU
Bmp4 transgenic mice (2) have argued against a negative foie for Bmp signais in the
differentiation of corticotrophs.
As an initial approach towards elucidation of the rote of Brnp signaling in
corticotroph differentiation, we studied regulation of proopiomeianocortin (POMC) gene
expression by Bmp signaling pathways in the corticotroph AtT-20 ceil une modei.
Previous analyses ofthe POMC (-4$0/+63bp) gene promoter known to confer corticotroph
specific activity (7;8) had impiicated distal and central regulatory elements in the
maintenance of promoter activity (9). In particuiar, ceii-specificity of POMC promoter
activity has been attributed to an interaction between bHLH transcription factors bound to
the distai domain, and Pitx homeodomain and Tpit T-box transcription factors bound to the
central domain (10-12). Tethered to the distal Ebox are bHLH heterodirners containing
NeuroDl/BETA2 factors that have Ebox0-specific binding activity. NeuroDi is
expressed in the developing pituitary exclusively in corticotrophs at a time (e12-e15) when
ACTH begins to be expressed. Its rote in the onset of corticotroph differentiation has been
recognized in NeuroDi nuii mice wherein the emergence of ACTH ceiis is deiayed
(Lamoiet B, unpublished). The dimerization partner ofNeuroDl, either the Pani (E12) or
the Pan2 (E47) ubiquitous bHLH factor, has been shown to participate in synergistic
protein:protein interactions with Pitx factors (11). The pan-pituitary Pitx factors have
indeed been assigned a centrai role in the combinatorial program that coordinates
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corticotrophic POMC expression, coïlaborating flot only with distal bHLH factors but aÏso
with the newly identified Tpit (11) (12). Obligate partners of one another, both Tpit and
Pitx factors are required for significant transcnptional activation of POMC promoter
activity in AtT-20 ceils. Unlike Pitx factors, Tpit stands out in its contribution to
corticotroph celi fate decisions because it is expressed solely in the pituitary POMC-lineage
from the time corticotrophs start to differentiate (12).
POMC expression in terrninally differentiated corticotrophs is regulated positively
by hypothalamic Corticotropin releasing hormone (CRH) and negatively by glucocorticoids
(Gc) (13-15). Signaling events that would coordinate the activities of POMC promoter
regulators, such as Pitx, Tpit and NeuroDl implicated in early pituitary developrnental
decisions have not yet been identified.
Tgf- cellular responses occur through changes in gene expression mediated for the
most part by the Smad family of transcription factors. Specific ligand-induced Tgf-3
serine/threonine receptor complexes recniit and phosphorylate receptor-regulated Srnads
(R-Smads): Smad-1/5/$ in response to Bmp and Smad2/3 in response to Tgf-3/Activin
stimulation (13-15). Activated R-Smads subsequently associate with the common-mediator
Smad4 (Co-Smad4) and translocate into the nucleus where they enable target gene selection
and either positive or negative gene regulation through tight collaborations with cell-type
specific transcriptionat partners. The list of Smad DNA-binding partners lengthens with
every new target gene characterized; some of the first characterized include the Xenopus
fAST-1 protein in the activation of Nodal-responsive Xenopus Mix.2 (16), the mouse
FAST-2 protein mediating activin-induced activation of the goosecoid gene (17) and the
OAZ protein in Bmp-mediated positive control of Xenopus Xvent-2 activity (18). Tgf-3
induction of transcription has been reported to occur either through the recruitment by
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Srnads andlor associated proteins of co-activators like p300, or through a derepression
mechanism that involves $mad-directed removal of negative regulators from their binding
sites (19). Tgf3-induced repression of transcription is less understood. Recentiy, Smad3
was shown to inhibit myogenic processes by directiy interfering with the transcriptional
activity of MyoD (20). HDAC-recruiting repressors such as Tumor growth inhibitory
factor (TGIF) (21), c-ski (22-24) and SnoN (25;26) have been implicated in the attenuation
of Smad activity. Other negative regulators of Smad signaling are Srnad6 and Srnad7
inhibitors that interfere with phosphorylation andlor nuclear transÏocation ofR-Smads (27).
An understanding of the molecular events underlying Bmp-specific Smad gene
responses is limited to the few natural Bmp target genes identified so far (2$). In
Drosophila, the Smadl/5/8 homologue Mothers against decapentaplegic (Mad) mediates
the induction of spait, optomotor btind, vestigiat, and Dad genes in collaboration with the
zinc finger transcription factor Scimurri (Shn) (29), and synergizes with Tinman to induce
the Timnan promoter (30). In mammals, Smadl and Smad4 together are able to confer
Bmp2-responsiveness to the human Id gene promoter independently of other transcription
factors (31), while OAZ is required to direct the same Bmp-activated Smad complex to the
Xenopus Vent-2 promoter (1$). 0f the Bmp responsive genes identified to date in
mammaïs, ail are positiveiy reguiated by Smad factors.
We show for the first time that Bmp-4 signaling negatively regulates endogenous as
well as luciferase (luc)-reporter POMC expression in AtT-20 as well as in P19 ceils. The
negative regulation of POMC promoter activity by Bmp-4 is rnediated by the classical
Smad signaling pathway since Bmp effects are mimicked and/or increased by the
overexpression of specific Activin-like kinase (Alk)-3/6 receptors and Smadl mediator
signaling components (32) and counteracted by the overexpression of the specific Bmp
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inhibitor Smad6, and the generai Tgf-3 inhibitor Smad7. Our studies moreover identify
Pitx homeobox and Tpit T-box transcription factors as targets of negative Bmp/Smad
activity. Direct in vitro binding of Smadl with Tpit and/or Pitxl suggest that protein
interactions wouid be the basis of Smad-directed interferences with Pitx- and Tpit- induced
transcription of POMC.
3.3 Experimental Procedures
Material
Recombinant (r) human Tgf-1, Activin-A, and Bmp-4 were purchased from R&D
Systems. Anti-Srnadl/5/8 (N-18) and anti-phopho-Smadl (Ser 463 and 465) antibodies
were purchased from Santa Cniz Biotechnology and Upstate Bioteclmology, respectively.
Anti-Pitxl and anti-Tpit antibodies were prepared in rabbits as described in (33) and (12),
respectively.
Plasmids and Ohgonucleotides
The different POMC reporter plasmids were constmcted in the vector pXP1-iuciferase (luc)
as described previously (34). Deleted versions of the —480/+63bp POMC prornoter
construct were generated as described previously (9). Ponctuai mutations and repiacement
of NurRE, Eboxneuto, Pitx, Tpit and Eboxb POMC regulatory elernents were described in
the work of (9). The simplified luciferase reporter piasmid with three copies of the 40-bp
POMC fragment oligo containing Pitx and Tpit regulatory elements was constructed as
described in (35). For Pitxl and Tpit expression vectors, Pitxl and Tpit coding sequences
were inserted in a RSV-driven vector as described in (12;36), and further rnodified with the
HindIILfKpnI insertion of a double stranded oligonucleotide con-esponding to the T3
promoter to allow the in vitro synthesis of Pitxl and Tpit. Expression vectors for 3TP-lux
Tgf-3 and T1x2-lux Bmp-responsive target gene reporters, constitutively active Bmp type I
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receptors and Srnad mediators were a gift from Wrana J and Attisano L (Hospital for Sick
Chiidren, Toronto, Canada), and have been described before: T1x2-lux (37); 3TF-lux (38);
pCMV5B/A1k3-HA (Q233D) and A1k6-HA (Q203D) (37;39); pCMV5B/Flag-Smadl,
flag-Smad2, Flag-Smad3, Smad4-HA and pGEX4T-1/Smad1 (37;40-42).
Ccli Culture and Iransfection Assays
AtT-20 (9) and CV-i (43) ceils were cultured in Dulbecco’s rnodified Eagle’s medium
(DMEM) with 10% fetal bovine seruin and penicillinlstreptavidin antibiotics, and
maintained at 37°C and 5% C02. CV-1 celis were transfected by the calcium phosphate
coprecipitation method. 40,000 ceils were pianted in 12-weii-plates. A total of 6 ug of
total DNA (3 ug of reporter plasmid, 0-1.5 ug of effector plasmid, 50 ng of CMV-
galactosidase as internai control), was used for each transfection, performed in duplicate.
Control experiments contained equivalent arnounts of empty expression vector and carrier
DNA psp64. 16 hrs afier transfection, medium was changed, and ceils were harvested 24
hrs later. AtT-20 cells were transfected using Lipofectamine (Pharnacia) as described
previousiy (11). Briefly, 250,000 cells/well were plated into 12-well plates; 1.5 ug total
DNA was used for each transfection, performed in duplicate (0.5 ug reporter, 0-1 ug
effector plasmid, 20 ng of CMV-J3-galactosidase as internai control and psp64) together
with 5 uL of Lipofectamine in a final volume of 400 uL without senim. After a 20 minute
incubation at room temperature (RI), the volume was made up to lmL with DMEM
without serum and left for 4 hrs on the ceils previousiy rinsed with DMEM without serum.
500 uL ofDMEM with 20% FBS was then added to each well, and the ceils were recovered
20 hrs later, using transfection lysis buffer (0.1M Tris pH 8.0, 0.5 % NP-40, 1 mM DTT).
Luciferase activity was assayed as described previously. -ga1 activity was determined
using the 3-gal reporter gene GalactoStarTM (TROPTX) assay system.
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RNA Isolation and Northern Blot Analysis
Total cellular RNA was isolated by the guanidium Thiocyanate-Phenol-Chloroforrn
extraction method (44). 10 ug RNA was anaÏyzed by electrophoresis on a 1.2 % agarose
gel by the RNA-glyoxal method (45). Transfer was perfonned on a Hybond-N
(Amersham) membrane. The RNA was crosslinked on the membrane, which was
incubated overnight in a pre-hybridization solution (4 X SET, 0.1 % Na-pyrophosphate, 0.2
% SDS and 100 ug/mL ofHeparin) at 65 oc. A 923-bp mouse (m)POMC cDNA fragment
was 32P-labelled as described in (43) and used to reveal endogenous mPOMc mRNA in
AtT-20 ceÏÏs. Hybridization and washes were performed as described in (43). f3-Actin
mRNA was revealed on the same Northern Blot using a 32P-labelled 13-actin cDNA
fragment that is described in (46).
RT-PCR
AtT-20 ccli RNA (2 ug) was used for cDNA synthesis with AMV reverse transcriptase
(Promega) according to manufacture’s intntctions. RNA extracted from e13.5 ernbryo
forelimbs was sirnilarly processed to obtain cDNA that was used as a positive control for
Alk receptor and Bmp ligand expression. Each PR reaction was performed for the
detection of Bmp-2, Bmp-4, Bmp-7 or Alk-2 transcripts as described in (12), whereas an
aimealing temperature of 47 oc was used for Alk-6. The primers used are the following:
Brnp-2 sens: AGACGTCCTCAGCGAATTTG Brnp-2 antisens:
GTTTGTGTTTGGCTTGACGC Bmp-4 sens: CGCCGTCATTCCGGATTACAT Bmp-4
antisens: GGCCCAATCTCCACTCCCTT Bmp-7 sens: GACATGGTCATGAGCTTCGT
Bmp-7 antisens: GTCGAAGTAGAGGACAGAGA Alk-2 sens:
GAGTGATGATTCTTCCTGTGC Alk-2 antisens: TTGGTGGTGATGAGCCCTTCG
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Alk-6 sens: TGGAGCAGTGATGAGTGTCT Alk-6 antisens:
TCTGGGTTCCTCTGTGTCTG.
Nuclear Extracts and Western Blot Analysis.
AtT-20 nuclear extracts were prepared by resuspending the cellular pellet in 400u1
cold buffer A (10 mM KC1, 10 mM Tris pH7.9, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM
PMSF, Ï mM DTT and protease inhibitors) and the suspension of ceils lefi to swell on ice
for 15 min. NP-40 (0.01 %) was added and the suspension was vortexed vigourously for
30 seconds. The suspension was gently spun down, the supernatant discarded, and the
nuclear pellet resuspended in 50 uL of cold Buffer C also containing protease inhibitors (20
mM Tris pH7.9, 400 mM NaCI, 1 mlvi EDTA, 1 mM EGTA, 20 mM PMSf, 1 mlvi DTT).
The nuclear suspension xvas shaken vigourously at 4 °C for 1 hr, then spun and the
supernatant assayed for protein content using the Bradford assay.
Western Blot analysis was performed as follows: 25 ug of AtT-20 nuclear
extracts/sample was resolved on 10% SDS-polyacrylamide gel, transferred to PVDf
membrane and irnmunoblotted with either 1:2000 dilution of anti-Pitx 1 antibody, 1:1000
dilution of anti-Tpit, or 1:1000 dilution of anti-phopho-Smadl antibody. Immunodetection
was possible with the use of horseradish peroxidase (HRP)-conjugated anti-rabbit antibody
(1:20000), followed by incubation with ECL Plus detection reagents (Arnersham Pharmacia
biotech).
GST protein purification and PuII-Down Assay
G$T and GST-$madl proteins were purified from BL21 bacterial celi cultures following
GST Gene Fusion System (Pharmacia Biotech) instructions. The yield of GST proteins
was assayed by Bradford and SDS-PAGE analysis. 35S Methionine-labelled Pitxl and Tpit
proteins were synthesized using the TNT-coupled transcription and translation system
(Promega) to manufacturer’s instructions, and assayed by SDS-polyacrylamide gel. 500 ng
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of purified GST and GST-Smadl ftision protein coupled to Glutathione Sepharose 4B
beads was incubated with 5 u! of radiolabelled Pitxl and/or Tpit proteins in 500 uL final
volume ofa buffer solution made up ofSOmM NaCÏ, 5OmM Tris pH 7.9, lrnM EDTA and
0.1 mM of NP-40, at 4° for 2 hours. The sepharose beads were then washed twice in
125nM NaC1, 50m1v1 Tris pH 7.9, lmM EDTA and 0.lmM ofNP-40 buffer; and twice in
200mM NaC1 50mM Tris pH 7.9, lmM EDTA and O.lmM of NP-40 buffer. Bound
protein complexes were eluted before being loaded on a 10% SDS-polyacrylamide gel.
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3.4 Results
Brnp-4 Downregutates POMC Expression in AtT-20 CeÏls AtT-20 ceils are a
corticotroph mode! ceil une that endogenously expresses the FOMC gene. b investigate
the role of Bmp signaling in regulation of POMC expression, we first determined whether
POMC rnRNA levels are affected by Bmp signais in AtT-20 ceils. AtT-20 celis were
incubated in presence of recombinant (r)Bmp-4 for 24 and 48 hours and FOMC expression
was assessed by Northen blot hybridization. As shown in Figure 3.1 A, rBrnp-4 reduced
POMC mRNA levels reaching near 60% repression within a 48hr period and without
affecting actin mRNA. These restiits are consistent with previous observations that
described downregulation ofACTH expression in e9.5 RP explants cultured in the presence
ofBmp2-coated beads (3).
b detemiine whether Bmp signaling negatively regulates FOMC expression at the
transcriptional level, a POMC (-480/+63) promoter-luciferase (lue) reporter construct was
transiently transfected into AtT-20 ceils and the response to rBmp-4 was assayed. rBmp-4
treatments downregulated POMC promoter activity in AtT-20 ceils in a time-dependent
(Fig. 3.13) and in a concentration-dependent manner (Fig. 3.1C). We observed a tivofold
repression of FOMC-luc basal activity in AtT-20 ceils following 8hrs of mM rBrnp-4
stimulation, and an almost maximal 80% loss of activity afier a 24hr treatment. When
tested for 24hrs, repression was nearly maximal (80%) with mM Bmp-4.
Bmp-4 repression is mediated through Bmp-speczfic receptors ami $madl/4
trcmscrlption factors — Bmp signais from the membrane to the nucleus are rnediated
through Bmp-specific receptors that activate R-Smads (Smadl,5,8). Brnp receptor type-I
ligand activation can be mimicked by mutations within the GS domain of Activin-like
kinase receptors (Alk)-3 and Alk-6 (39), so that Alk-3(Q223D) and Aik-6(Q203D)
constitutively activated mutants can signal in the absence of ligand. To assay whether Bmp
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repression of FOMC activity in AtT-20 celis is mediated by the activation of Bmp-specific
receptors, expression vectors encoding Alk-3(Q223D) and Aik-6(Q203D) were used in
transfection assays. Overexpressed Aik-3 and Alk-6 decreased FOMC-luc activity to leveis
similar to those generated through r3mp-4 stimulation (Fig. 3.2A). In subsequent assays,
250 ng of Aik-3(Q223D) was used as an alternative for mM rBmp-4 treatments.
If Smadl participates in Bmp-rnediated repression ofPOMC in AtT-20 celis, then its
overexpression would be expected to increase the sensitivity of AtT-20 ceils to exogenous
Bmp signais and hence enhance Bmp-4 inhibitory effects on POMC. When Fiag-Srnadl
and/or Smad4-HA were transientiy overexpressed in AtT-20 ceils, Bmp4-rnediated
repression of POMC-iuc activity was significantiy enhanced (Fig. 3.23). The fourfold
inhibition of FOMC promoter activity encountered upon the overexpression of Smadl/4 in
the absence of Bmp treatment is an indication that endogenous Bmp signais might aiready
be present in cultured AtT-20 celis to activate Smad proteins. It moreover seems that a
limiting amount of free $madl and Smad4 are available in AtT-20 celis to participate in
Bmp signaling since the addition of Smads in these ceils significantly enhances Bmp
reponses (Fig. 3.2B). In unstimulated P19 ceils, overexpression of Smadl and Smad4 only
slightly repressed FOMC promoter activity, and this effect vas not observed in Bmp
stimulated conditions. Saturating levels of Smadl and Smad4 may be present in P19 ceils
or alternativeiy, the ceiluiar context of AtT-20 celis is particuiariy suited for Bmp rcpressor
effects on FOMC transcription.
$madl is the best-characterized intraceliular transducer of Bmp signais. Activation
of cytoplasmic Smadl by Bmp receptors is characterized by the phosphorylation of
carboxy-terminai serines 462, 463 and 465, and subsequentiy transiocation into the nucleus.
To determine whether endogenous Smadl is indeed activated in AtT-20 celis foiiowing
rBmp-4 treatments, nuciear protein extracts of rBmp4-stimulated and non-stimulated celis
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were imniunoblotted for the presence of phosphorylated Smadl using an Upstate
Biotechnology antibody specific for serines 463/465 phosphorylated Srnadl. As shown in
Fig. 3.2C, small amounts of phosphorylated Smadl are present in unstirnulated AtT-20
celis, constitent with constitutive Bmp signaling in these ceils. Upon rllmp-4 stimulation,
nuclear phosphorylated Smadl was increased, peaking 24 hrs after rBrnp-4 addition. When
cultured AtT-20 celis were assayed for Brnp ligand and/or receptor expression using RT
PCR techniques, they were found to have transcripts for Brnp-7, as weIl as for Alk-2 and
A&-6 Bmp-specific type-I receptors (data flot shown). Alk-2 and Alk-6 type I receptors
have been reported to function in the activation of Bmp-specific R-Smads following ligand
stimulation (47), thus we have shown that AtT-20 cells are Brnp-responsive and that they
possess the appropriate machinery to convey Bmp signais to the nucleus through Smadl
activation. Brnp-7 appears to be the active endogenous Ïigand in AtT-20 celis.
BMF/Smad] signaling specfically represses POMC promoter activity —
Bmp/Smadl signaling is known to activate transcription ftom the mouse Ttx-2 prornoter in
P19 cells (37). We first asked whether the same Bmp- signaling pathway may repress
POMC and activate T1x2 promoter activity. In AtT-20 ceils, we show that whereas Alk-3
and Smadl/4 overexpression represses POMC-luc activity by at least twofold, it does flot
repress T1x2-lux activity but induces it weakly (Fig. 3.3A). FOMC-luc and T1x2-htx
promoter activities responded in a similar fashion to Bmp signaling in P19 celis, but with a
noticeable difference in response sensitivity of T1x2-lux (Fig. 3.33). The relatively weak
induction of TÏx2 in AtT-20 celis may be due to the lack of a Smadl partner in these ceils
compared to P19 celis. Clearly however, the inhibitory effects ofthe Brnp pathway on the
POMC promoter are promoter-specific and do flot reflect a general cellular response.
Different members of the Tgf-3 superfamily of growth factors were tested for the
specificity of their effects on POMC promoter activity in both AtT-20 and P19 ceils. The
69
T1x2-lux and 3TP-lux reporters were used, respectively, as controls of Bmp- and Tgf3-
dependent signais (37;4$). By showing that 3TP-Ïux activity is induced in AtT-20 ceils
upon treatrnent with rActivin or rTgf-f3, we verified that AtT-20 celis are responsive to
different members of the Tgf-3 family of growth factors (Fig 3.3C-D). POMC prornoter
activity was repressed by 75% in AtT-20 celis and by 50% in P19 celis treated with rBrnp-4
(mM) or rActivin-A (500pM), but was not affected in either celi type challenged with Tgf
13 (lOOpM) (Fig 3.3C-D). The Activin-mediated repression of POMC prornoter activity
observed in AtT-20 celis is in support of previous work showing reduced accumulation of
secreted ACTH upon Activin-A treatment (49). Also highlighting their difference in
signaling, rActivin, but not rBmp-4 treatment, repressed T1x2 promoter activity in AtT-20
ceils (fig. 3.3C).
Whiie the intraceliuiar activity of Smadi is specific to Bmp responses, $mad2 and
Smad3 activities have been assigned to Activin and Tgf-13 signaiing pathways (50). To
determine whether Activin iiihibitory effects on POMC expression may be mediated by
Smad2 and/or Smad3 in AtT-20 ceils, increasing concentrations of Flag-Smadl, Flag
Smad2 and FIag-Smad3 were overexpressed in these ceiis and the activity of POMC-luc
assayed. Oniy overexpressed Smadl was efficient in blocking transcription from the
POMC promoter (Fig. 3.3E). The inability of Smad2 or Smad3 overexpression aione at
mimicking inhibitory Activin effects may suggest that Srnad-independent pathways are
acting downstream of Activin to repress POIvIC in AtT-20 celis. Ultimately, the role
Smad2 and/or Smad3 play in activin-induced repression of POMC activity will be
addressed through the use of Smad dominant negative forms. Notably, FOMC-luc activity
was slightly decreased with higher concentrations of Flag-Srnad3 (0.5-lug), however the
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loss ofFOMC activity was accompanied by a similar reduction in the activity of CMV-f3gal
used as internai control (data not shown).
$mad6 and $mad7 counteract Bmp-mediated repression of POMC — Smad6 and
Smad7 are known inhibitors of Tgft3-induced cellular responses. The downregulation of
POMC promoter activity following Bmp-4 treatment or Smadl/4 overexpression was
compÏetely blocked by overexpression of the Brnp-specific inhibitor Smad6 and the general
Tgf- inhibitor Smad7 (Fig. 3.4). Notably, basal levels of POMC expression in AtT-20
ceils were augmented by the overexpression of Smad6 and Smad7, indicating once more
that endogenous Bmp signaling pathways negativeiy control POMC promoter activity in
these cells.
Negative Bmp/Sinad signais target Pitx/Tpit activities on the POMC promoter —
The POMC promoter has been divived into three regions; namely, distal (-4$O/-324bp),
central (-323/-166bp) and proximal (-165/-34bp) regions (9). In an attempt to identify
POMC promoter sequences that are responsive to Bmp/Smad signaling, we tested the Bmp
4 response of constrncts containing these promoter regions, alone or in combination.
Previous studies in our laboratory had shown that central and distal domains act in synergy
and that this synergism is celi-specific (9;51). Oniy the reporter construct containing both
distal and central POMC promoter regions responded to rBmp-4 stimulations to the same
extent as did the full-length prornoter (Fig 3.5A). These resuits suggest that Bmp signaling
negatively targets synergistic activities acting on the distal and central domains of the
POMC promoter.
The distal and central domains of the POMC promoter contain most of the critical
regulatory elements for ceil-specific recognition, for synergism between the two domains,
as well as for hormone response (1O;12;52). We used element-specific mutants to
71
determine which is/are required for Bmp inhibitory signaling. Mutagenesis of either
NurRE element that confers hormone responsiveness or of the EbOXneuro that confers ceil
specific recognition by neurogenic bHLH factors and synergism with the central promoter
domain did flot affect Bmp4 responsiveness (Fig. 3.5B). However, Bmp-4 sensitivity was
lost upon mutagenesis ofeither Pitxl or Tpit binding sites.
Tpit, a newly identified member of the T-box transcription factor family (12),
synergizes with Pitx on respective binding sites which are only 5 bp away from each other.
Together, Pix and Tpit binding sites comprise the central regulatory element that
participates in synergistic interactions with NetiroD 1 -containing bHLH heterodimers acting
on the distal promoter E bOxneuro (1O;11). The restricted action of Bmp-4 on Tpit/Pitxl
indicates that it is their activity itself rather than their synergism with NeuroD 1 dimers that
is targeted by Smad action. In order to verify this, a reporter construct driven by
oligotrimers containing Pitx/Tpit response elernents (12) was transfected in CV-1 celis and
found to be repressed by Alk-3 (Q223D) (Fig. 3.5C). Their repression was rnost evident in
the presence of both Pitx 1 and Tpit, but a similar tendency was also observed on Tpit
dependent activity. Since Bmp4-expressing epithelia have been docurnented to repress
Pitxl expression in mandibular mesenchyme (53), we analyzed whether activation of the
Bmp-4 signaling pathway in AtT-20 celis affected the expression of Pitxl and/or Tpit.
Nuclear protein extracts from AtT-20 celis treated or not with rBmp-4 were assayed by
Western Blot for Pitxl and Tpit protein levels. No change in Pitxl or Tpit protein
expression was detected (Fig 3.5D), in agreement with data from Figure 3.5C.
Smad], Pitx] and Tpitproteins intentez’ in vitro — One manner in which Bmp-activated
Smadl could interfere with the transcriptional activities ofPitx and Tpit in AtT-20 celis
would be through protein:protein interactions. With this in mmd, purified GST and GST
Smadl fusion proteins were assayed for binding to 35S-labelled, individuaÏly- or co
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translated Pitxl and Tpit proteins. GST-Smadl bound to resin was able to pull-down Pitxl,
Tpit, or both protein, whereas the GST rnoiety alone could not (Fig. 3.6). In vitro translated
luciferase did not interact with either GST or GST-Srnadl. Bmp signaling rnight hence
interfere with transcriptional activation ofthe POMC gene tÏirough the recruitment of
Smadl by Pitx and Tpit factors.
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3.5 Discussion
The identity of a corticotroph ceil is determined by a developrnental program that
impÏicates the activities of Pitx and Tpit factors. Pitx and Tpit participate in synergistic
interactions that are the basis of ceil-specific POMC expression. We have shown that
Bmp- and Smadl-specific signaling pathways repress POMC expression in AtT-20 ceils,
and we propose that Smadl antagonistic interactions with Pitx and Tpit transcription
factors form the basis of this repression.
Bmps had to date oniy been characterized as inductive signaling molecules in
mammals, activating the expression of the T1x2 homeobox gene for example (37). We
show for the first time that Bmp-4 signaling represses endogenous POMC expression in
AtT-20 celis as well as POMC (-480/+43) prornoter-luciferase reporter activity. We also
show that the classical cognate receptor/Smad signaling pathway conveys Bmp signais to
the nucleus in AtT-20 celis to repress FOMC expression. Indeed, Bmp inhibitory effects on
POMC promoter activity observed in rBmp4-treated conditions could be mimicked with the
overexpression of the Bmp-specific intracellular mediator Smadl and with constitutiveiy
activated forms of either Alk-3 or Alk-6 Brnp receptors. Recently, other signaling
pathways such as the cascades that implicate extracellular signal-regulated kinase (ERK),
protein kinase C (PKC), cAMP-dependent protein kinase A (PKA), and Tgf-activated
kinase-1 (TAK1) activities have been implicated in Brnp responses (54-57). In light ofthis,
there was a possibility that Smad-independent pathways might be involved in Brnp-induced
effects on FOMC expression is not excluded. However, Srnad6 and Srnad7 overexpression
studies suggest that Brnp-induced inhibitory FOMC responses are principally rnediated by
the Smad signaling pathway.
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It appears that different members of the Tgf-f3 superfamily may repress POMC
expression. We observed that rActivin-A, but flot rTgf-3 treatrnents of AtT-20 celis
repressed POMC expression to a similar extent as did rBmp-4 treatments. Others had
implicated Activin-A in the inhibition of POMC mRNA accumulation and ACTH secretion
from AtT-20 celis (49) and also Tgf-3 was shown to inhibit POMC rnRNA in hypothalamic
neurons (58). Our failure to observe Tgf-f3 downregulation of POMC expression in AtT-20
celis may be due to the use of the POMC (—4801+63) promoter region in our assays, which
does not contain regulatory sequences regulating hypothalamic expression of POMC (59).
Although we did detect transcripts encoding for the Alk-2 type I Tgf-13 receptor in AtT-20
celis which is known to mediate common responses to Activin and Bmp-7 (47) and
although Tgf- and Activin responsiveness was shown in AtT-20 celis (fig 3.3C), we could
not detect activation of the Smadl signaling pathway in rActivin-treated AtT-20 celis. We
were moreover unable to detect any effects on POMC promoter activity following the
overexpression of Activin-specific Smad2 and Smad3 at concentrations for which Smadl
inhibited POMC expression, suggestive of a Smad-independent effect of Activin and Tgf-
on POMC expression in AtT-20 ceils. In muscle celis for example, Tgf3-mediated
repression of IGFBP-5 expression lias been described to occur through c-Jun N-terminal
kinase (JNK) signaling pathways (60).
Smad transiocation into the nucleus is known to require ligand stimulation,
suggesting that the mere presence of supplementary Smad mediator proteins rnight flot
suffice to affect gene responses in cells. However, some groups have dernonstrated that
transiently overexpressed Smad proteins are able to transactivate target genes in a ligand
independent manner (61;62). We found that overexpression of Smadl alone or in
combination with Smad4 could repress POMC expression up to fourfold in AtT-20 ceils
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even in the absence of exogenous Bmp stimulation. However, overexpressed $madl could
be acting in a ligand-independent manner if supplernentary arnounts of Srnadl were to
overcome sorne mechanism of negative signaling regulation established in AtT-20 ceils,
such as inhibitory Smad6 or Smad7 expression or simply microtubule Smad sequestration
(27). Stiil, evidence that Bmp7 signaling pathways may endogenously be activated in AtT
20 celis is in favor of a ligand-dependent activity of overexpressed $rnadl in these celis.
Our findings that overexpression of Smad6 or Smad7 could reverse POMC repression by
Bmp signais, whether they are endogenous or exogenous, furthermore suggests that similar
Bmp antagonists might 5e working against Bmp/Smad-mediated repression of FOMC
expression.
Smadl and Alk-3/-6 signaling components shown to repress FOMC expression
when overexpresssed, also induce transcription from the T1x2 promoter (37). Srnad
interactions with different FOMC and T1x2 promoter-specific transcription factors are likely
responsible for the opposite Bmp responses observed. fndeed, Smad binding to DNA is not
selective (63), and gene recognition by the Srnad complex has been recognized to occur by
way of interactions with specific transcription cofactors. Srnadl-rnediated induction of
Xvent-2 expression for example requires cooperation with the Omithine decarboxyiase
antizyme (OAZ) transcription factor (18). Differentiai Smad interactions with FOMC and
T1x2 promoter-specific transcription factors are the likely explanation for the difference in
Bmp responses we observe, which presumably originates from promoter-specific
differences in Smad activity. A Smad DNA-binding partner that wouÏd make possible the
activation of T1x2 transcription lias yet to be elucidated. Our studies support an essential
roie for Pitx and Tpit transcription factors in Smad-rnediated repression of POMC
expression. Not only are Pitx and Tpit regulatory elements important for induction of
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POMC transcription (12), but we show that loss of either activity abolishes repression of
the POMC promoter by Bmp (Fig. 3.63). These findings suggest that Pitx and Tpit
transcription factors are the principal coordinators of negative Smad action on the POMC
promoter. The in vitro interaction of Smadl with Pitxl and Tpit is consistent with a role
for these homeobox and T-box factors in POMC repression. Smad2 has been shown to
interact with paired-like homeodomain proteins of the Mix family, Mixer and Milk,
through a smad-interacting motif that is also found in members of the FAST family of
winged-heiix transcription factors (64). We couid not locate such motif in bicoid-reiated
Pitx homeodomain proteins. There are no precedents for interactions between members of
the T-box and Smad families.
Pitx and Tpit factors are obligate partners of one another for POMC activation (12).
Bmp signaling in heterologous CV-1 celis being able to block Pitx/Tpit synergistic
interactions that relie exclusively on their respective binding sites suggests that Pitx and
Tpit regulatory elements are afler ail direct targets of Brnp signais in corticotrophs. How
exactly Bmp-activated Smads antagonize with Pitx and Tpit-dependent POMC
transcription remains to be ciearly explained. Smad interactions with DNA-bound Pitx and
Tpit factors could interfere with their transcriptional activity by acting directly on the
transactivation domains of these activators or by interfering with the recmiternent by Pitx
or Tpit of yet undefined co-activators. Another way the Smad complex could remodel the
chromatin template into a closed conformation would be through the recniitment of
HDACs. For example, Smad2 has been shown to act as a repressor of transcription by
associating with TGIF in the repression of the Cdc25A promoter for example (65). Brnp
activated Smad proteins couid also be competing with Pitx and/or Ipit binding to DNA.
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Also, activated Smadl induces the expression from the osteopontin promoter through its
ability to sequester the Hoxc-$ repressor away from DNA.
Repression of gene activity plays an important role in the restriction of many
regulatory genes during embryonic development. Tgf- was recently implicated in the
inhibition of myogenic differentiation through Smad3-mediated repression of MyoD
transcriptional activity (20). In a similar fashion, Smadl/4 antagonistic interactions with
Pitxl an&or Tpit could act to negatively modulate FOMC prornoter activity in
corticotrophs, either for appropriate timing of differentiation during developrnent or for
coordination of POMC expression in response to signais elicited by other ceils involved in
pituitary function. The use of AtT-20 celis is limited subsequently the relevance of Bmp
signaling in the timing or maintenance of pituitary corticotroph differentiation will require
conditional gene-targeting studies in mice. Investigating the molecular basis of Bmp
participation in corticotroph celi phenotype determination and differentiation should give us
a due of the implications of these pathways flot only in developmental processes, but also
in pituitary function and possibly in tumorigenesis.
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3.7 Figure Legends
fig. 3.1 Bmp-4 represses POMC expression and promoter activity. (A) Northern biot
analysis of POMC mRNA in AtT-20 ceils treated with mM Bmp-4 for 24 and 48 hrs,
compared to non-treated celis. Bands corresponding to POMC rnRNA were quantified by
densitometry and compared to 13-actin mRNA used as internai control. (B and C) Effect of
r3mp-4 on AtT-20 ceils transfected with a luciferase reporter gene driven by the FOMC
promoter (-4801+63). (B) rBmp4 (mlvi) represses FOMC-iuc activity in a time-dependent
maimer. (C) Dose response of FOMC promoter repression by rBmp-4 measured afier 24hr
treatment. Resuits in (B) and in (C) are for representative experiments in which luciferase
values were standardized relative to CMV-f3gai reporter activity as internal control.
Fig. 3.2 Bmp-4 repression is mediated through Bmp-specific receptors and Smadl/4
transcription factors. (A) Overexpression of increasing amounts of constitutively active
Alk-3 (Q223D) and Alk-6 (Q203D) receptors downregulates FOMC-iuc reporter activity in
AtT-20 ceils to similar or greater levels than those observed in cells stimulated with rBmp
4. pcDNA 1 was used as control vector. (B) Flag-Smadl (Si) overexpressed alone, or
together with Smad4-HA (S4), represses FOMC-luc activity when transfected in AtT-20
and P19 ceils, and furthermore enhances Bmp inhibitory effects in AtT-20- cells. (C)
Foilowing 4, 24 and 48 hr mM Bmp-4 treatment of AtT-20 celis, nuclear extracts (25ug)
were assayed for content ofphosphorylated Smadi protein using an Upstate Bioteclmology
antibody against Smadl phosphorylated on Serine 463 and 465 of the C-term 55X5 motif.
The 65 kb band may correspond to phosphorylated Smadl (arrow), while the slower
migrating hand may be another Bmp-specific Smad, such as Smad5 or Smad8. Resuits are
the average (± standard error of the mean [SEM]) from at ieast three sets of experiments
performed in duplicate.
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Fig. 3.3 Bmp/Smadl signaling specifically represses POMC. Tri both AtT-20 and P19,
overexpression of Alk-3 and $rnadl (A,B) as well as rBmp-4 treatrnents (C,D) repress
FOMC-Ïuc but not TÏx2-luc or 3TP-lux reporter activities. Noteworthy is the greater
sensitivity of POMC promoter activity to Bmp/Smad-mediated repression in AtT-20 celis
than in P19 celis. POMC-Ïuc activity is also repressed by rActivin-A, but flot rTgf-t3
treatments (C, D). T1x2-lux activity is induced by Smadl/4, Alk-3 and Brnp-4 in P19 ceils
(B,D), but only by Smadl/4 and Alk-3 overexpression in AtT-20 ceils (A). The Tgf
specific 3TP-lux reporter is activated in both P19 and AtT-20 ceils by rActivin and rTgf-3,
but not by rBmp-4. (E) Increasing concentrations of Flag-Smadl, but not Flag-Smad2 or
Flag-Smad3 repress the activity of FOMC-luc transfected in AtT-20 celis. Results are the
average (± standard error of the mean [SEM] from at least three sets of experiments in
duplicate).
Fig. 3.4 Inhibitory Smad6 and Smad7 reverse Bmp/Smad-dependent POMC
repression. Increasing concentrations of the Brnp-specific inhibitor Smad6 (A) and the
general Tgf-3 inhibitor Smad7 (B) counteract the repressive effects of Smadl/4
overexpression and rBmp-4 treatment on POMC-luc activity in AtT-20 ceils. Resuits are
the average (± standard error of the mean [SEM] from at least three sets of experirnents in
duplicate).
Fig. 3.5 Bmp signais target Pitxl and Tpit regulatory elements on POMC. (A) Bmp4-
responsiveness of distal, central and proximal regions of the -480/-34 POMC promoter,
alone or in combination, and upstream of the minimal (-341+63) POMC prornoter were
tested in Bmp4-treated AtT-20 cells, and are shown relative to their respective basal
activities in non-treated cells. Only the combined activity of distal and central promoter
regions, in a similar fashion to the (—480/+63) full-lenght promoter, is repressed by Bmp
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signaling. (B) Relative activities (Bmp4-treated vs. —nontreated) of replacement mutants of
either NurRE, EbOXneuro, Tpit, Pitx 1, and Eboxb regulatory elements within the rPOMC
promoter. The loss of Tpit or Pitx regulatory elements abolishes Bmp-4 repression (C)
Overexpression of constitutively active Alk-3 (Q223D) receptor in heterologous CV-1 ceils
represses Tpit-dependent, as well as Pitxl and Tpit-dependent activities. Resuits are the
average (± standard error of the mean [SEM]) from at least three sets of experiments in
duplicate. (D) Phosphorylated Smadl, Pitxl and Tpit protein levels were assayed by
Western Blot in nuclear extracts of control AtT-20 cells, and treated with mM rBmp-4 for
4, 24 and 48 hrs. The amount of nuclear Pitxl and Tpit transcription factors is not
downregulated with increased nuclear Srnadl activity in AtT-20 celis.
Fig. 3.6 Smadl interacts wïth Pitxl and Tpit in vitro. In pull-down assays, GST resin
bound Smadl (GST-S1) but flot resin control (GST) pulled down 35S-labelled Pitxl and
Tpit proteins synthesized seperately or cosynthesized in vitro. In vitro translated S
labeled luciferase did not bind to either GST or GST-$ 1.
Fig. 3.7 Model for Bmp-induced transcriptional repression of POMC. A $madl/4
complex transiocates to the nucleus upon Brnp-stimulation, is recruited to the POMC
promoter by Pitx and Tpit and subsequently disrnpts transcriptional synergism between
Pitx/Tpit factors bound to the POMC promoter in the central region.
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CHAPTER4- DEFINING THE MECHANISM 0F ACTION 0F BMP-SPECIFIC
SMADS ON THE POMC PROMOTER
During my Master’s project, I was able to show that POMC expression is repressed
by a Smad-rnediated Bmp signaling pathway that appears to target Pitx and Tpit
transcriptional activities in the central prornoter region. Work to determine how Bmp
activated Smads act, directly or indirectly, on Pitx and Tpit regulatory elements to
subsequently repress FOMC transcription is ongoing, and for this reason I omitted it from
my article preferring to present this incomplete portion of my graduate studies as a separate
chapter in rny thesis. Any relevant information this work should provide to elucidate the
mechanism of Brnp-specific Smad action on the POMC prornoter is to be included in my
article to allow for a more thorough understanding of Smad-mediated repression of POMC
transcription. Such findings may open the way to understanding the so far unresolved role
that Smad proteins, and especially Bmp-restricted Smads play in transcriptionally
repressive complexes.
4.1 DNA-Binding Activity of Smad Proteins
Smad proteins are known as independent and sequence-specific DNA binding
proteins that regulate transcription mostly, if flot solely with the collaboration of DNA
binding partners. As mentioimed in the introduction, the consensus sequence 5’-AGAC-3’
that has corne to be known as the Srnad-binding-elernent (SBE) has been dernonstrated to
be critical for Srnad binding and activity on target promoters. Unfortunately, most of the
early work that looked at the regulative role of the SBE in transcription was performed on
TgfT3- and Activin-inducible genes (55,91,275). As much as some studies have
characterized SBEs as functional binding sites in Bmp-responsive prornoters such as in the
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Id promoter (116,148), certain studies have dernonstrated that SBE sequences are flot high
affinity binding sites for Bmp-regulated Smads, as is the case in the JïtizB (104) and PAl-]
(52) promoters. Another Smadl-binding element was identified in Bmp-responsive Id
(116,148) and Msx] (5) promoters, and consists of a GC-rich sequence that resembles the
Drosophila Mad recognition site (112). Indeed, Dpp responses in Drosophila are elicited
by the binding of Smadl-related Mad to GCCGnCG promoter sequences, and cooperation
with sequence-specific transcription factors (112,202).
Stiil not clearly defined in the field of Bmp and moreover Tgf-3 signaling is
whether Smad binding to DNA is required for Smad action on nuclear targets. The
osteopontin-inducing activity of Bmp for example appears to relie solely on Smadl protein
interactions with the Hoxc-8 transcriptional repressor, for which access to prornoter binding
elements is subsequently denied.
4.2 SBEs in the POMC Promoter: Prelimïnary Resuits
The difficulty in identifying Bmp-responsive sequences in the POMC promoter is
that nothing is known of how Bmp-specific Smads actively repress genes, and only a few
cases have been described of Smad3-mediated Tgf-f3 inhibition of gene transcription
(4,84,142). The mechanism of Smad transcriptional repression that is the most clearly
defined in these studies describes the ability of Smad3 to inhibit muscle creatine kinase
transcription by directly interfering with the transcriptional activity of MyoD-containing
bHLH heterodimers (142). In this context, Srnad3 does not appear to require binding to
DNA to repress the activity ofMyoD, which raises the question ofwhether a Smad-binding
site is really mediating Bmp responses on the POMC promoter. Other studies have
reported the recruitment of Smad-interacting repressor molecules (Sno, Ski, TGIF) and
HDACs to Tgf3-responsive promoter SBEs, but in this case to tum off Smad activity (279).
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Interestingly, unpublished data proposes that a binding site that differs from the
characterized SBE, which has been associated with transcription activation, would be
mediating transcriptional repression by Tgf-f3 (Wang X.-F., unpublished).
My search for a Smad-binding element in the POMC promoter was focused on the
40-bp promoter element that includes Pitx and Tpit binding sites since this POMC sequence
was sufficient to mediate Bmp inhibitory effects on Pitx and Tpit-dependent activity in
heterologous ceils (Figure 3.5C). As shown in figure 4.1, the analysis of FOMC prornoter
sequences located within and around Pitx and Tpit binding sites for putative SBEs resulted
in no perfect match for the 5’-AGAC-3’ consensus, but quite a few sequences (shown in
boxes) harbouring one mismatched nucleotide were identified. Although the same POMC
fragment contains some scattered GC-rich clusters of nucleotides, none of these correspond
to the characterized GCCGnCG Mad-like consensus binding site (263). One of the
experimental approaches used to assay whether any one, or more likeÏy a combination of
these sites mediates the Bmp response on FOMC, was to resort to site-directed
mutagenesis. I made use of available reporter plasmids driven by three copies of a wild
type (WT) or 3-bp mutant oligonucleotide conesponding to the 40-bp FOMC fragment, and
analyzed their transcriptional activity in A1k3-transfected and non-transfected AtT-20 celis.
Resuits from this analysis are summarized in Figure 4.2. The wild-type construct was
consistently observed to loose 50% of its activity in A1k3-overexpressing AtT-20 celis,
confirming that the 40-bp POMC promoter fragment containing Pitx and Tpit regulatory
elements is a direct target of Brnp signais in these ceils. Noteworthy in the latter
experiment is: firstly, that the M5 FOMC-luc mutant reporter that contains mutations
within the Tpit binding site was less repressed than the WT construct in AtT-20 celis
transfected with Alk-3; and secondly, that the M 16 POMC-luc mutant containing mutant
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nucleotides between the Pitx and Tpit regulatory elements also exhibited decreased
repression. The observation that nucleotides located between Pitx and Tpit binding sites
are partially implicated in FOMC repression by Bmp signaling suggest that these
nucleotides miglit be mediating Smad action through Smad binding to DNA.
Loss of Bmp-response from the M5 FOMC oligo constnict bearing mutations
within the Tpit binding site xvas predicted by previous findings that showed a requirement
for this site in the ability of the 480-bp (full-length) POMC promoter fragment to
negatively respond to Bmp treatments (Figure 3.5B). However, the two different mutations
of the Pitx binding site (in which different nucleotides are targeted) have different
outcomes. In the context of the full-length promoter, Pitx binding site mutation abolished
almost entirely POMC response to Bmp (figure 3.5B). On the other hand, the M8 4Obp-
POMC oligo trimer construct containing rnutated Pitx sequences previously demonstrated
to play an important role in Pitx/Tpit synergistic activities (127), was repressed as much as
the WT constmct in A1k3-overexpressing AtT-20 celis. Is the Pitx binding site hence really
important for Smad-mediated transcriptional repression of POMC activity? Other Pitx
mutations will be analyzed to answer this question.
b deterrnine whether FOMC promoter nucleotides that span or surround Pitx and
Tpit regulatory elements can bind Smad proteins, I tumed to the EMSA technique. I
assayed whether bacterially-expressed GST-Srnadl moieties could directly bind to a 40-bp
DNA probe corresponding to the same oligo POMC sequences rnentionned above and
shown in Figure 4.2. I show that aÏthough both 1 ug of GST-Smadl and lug of GST
Smad4 are able to bind a probe containing four repeats of the JuizB promoter SBE
(4XSBE), only GST-Smadl binds to the 40-bp POMC probe (Figure 4.3). The binding
affinity of GST-Smadl to the POMC probe is much lower than that observed for the
4XSBE probe, suggesting that the putative SBE in the FOMC sequence fragment is of low
Figure 4.3 GST-Smadl binds to FOMC promoter nucleotides located h proximity
to Tpit- and Pitx-regulatoiy elernents in the central region.
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affinity and is probably flot present in multiple copies. The 4XSBE probe should hence, for
comparison purposes, be replaced by a lower-affinity 2XSBE or 1XSBE probe when a
positive control is to be used. Seeing that GST-Smadl is not phosphorylated, it should be
mentioned that the ability of Smadl to interact with DNA in rny EMSA essays may not
necessarily reflect the DNA binding properties of phosphorylated Smadl in the Bmp
activated celi.
I verified that the GST-Smadl shifi that I observe with the POMC probe could be
supershified with an antibody that recognizes Smadl, Smad5 or Smad8 (Santa Cruz N-1 8).
I found that a Smad-1 supershift worked best following a 20 minute incubation on ice of
the antibody with the protein:DNA mixture, itself previously inctibated on ice for 40
minutes (figure 4.4). The antibody on its own did not yield any similar migrating band in
the same gel (data not shown).
4.3 SBEs in the POMC Promoter: Perspectives for the Future
A good deal of work is yet to be done to properly understand how Bmp-activated
Smad proteins interfere with the activity ofPitx and Tpit transcription factors on the FOMC
promoter in corticotroph celis. Through the genetic analysis of different mutant forrns of
POMC fragments, it appears that nucleotides lying behveen Pitx and Tpit binding sites play
an important role in mediating Bmp-inhibitory effects on the promoter. Upon showing that
GST-Smadl, and not GST-Smad4, binds to this POMC promoter fragment in EMSA
assays, I immediately tested the role that nucleotides between Pitx and Tpit regulatory
elements might be playing in Smad DNA binding. I observed that G$T-SmadÏ moieties
bound to the M16 probe as well as to the WT probe (data flot shown), implying that the
aforementionned nucleotides are not required for Smad binding. It is possible that these
inner nucleotides might coordinate the anchoring of some repressor protein that is recniited
by the Pitx/Tpit-bound Smad complex to negatively regulate transcription from the POMC
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promoter. Such a repressor protein underlying POMC negative responses to Bmp
challenges could be the TGJF transcription factor, recently implicated in the negative
regulation ofTgf-3 responses (25$). Although an optimal DNA binding sequence for TGIF
has been identified in vitro (12), it is flot yet known whether TGLF binding to DNA plays
an important role in modulating Tgf-3 responses. Some simple ways of determining
whether TGIF is recruited to the POMC promoter would consist in using the EMSA
technique to determine in one case whether GST-TGIF fusion proteins are able to bind to a
FOMC probe in vitro, and in the other case to show in vivo TGIF-binding activity in AtT
20.
Much work is still required to understand the role that Smad binding to POMC
plays in corticotroplis to repress transcription in response to Bmp signais. The EMSA
technique shouid be helpful in identifying Smadl-binding elernent(s) within the Brnp
responsive 40-bp POMC promoter fragment. That is, different mutant POMC probes wili
be tested for their ability to bind GST-Smadl in comparison to the WT POMC probe. In
paraliel, it would be nice to show binding of a Smadl-, Smad5- or Smad$-containing
complex in nuclear extracts from Bmp-treated AtT-20 cells to corroborate in vitro resuits
obtained with GST-Smad proteins. The latter information can be obtained through the use
ofEMSA as weii as chromatin immunoprecipitation (ChIP) techniques.
Another question that should be deait with concems the effect that Smad binding to
DNA might have on the DNA-binding activity of Pitx and Tpit. Again, an in vitro
approach is probably the quickest in providing us with some answers. The idea is to assay
any changes that might occur in the abiiity of MBP-Pitxl andlor in MBP-Tpit to bind the
40-bp FOMC probe (127) upon the addition of GST-Smadl moieties. If Smadl blocks
Pitxl or Tpit binding to FOMC, respective shifts are expected to disappear compÏetely or
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partially in presence of GST-Smadl. Altematively, Smadl-Pitxl or Smadl-Tpit migbt
form POMC-binding complexes that would be transcriptionally-impaired; such complexes
would be expected to be supershifled by an a-$madl antibody, but also by either the Œ
Pitxl or the a-Tpit antibody. ChIP assays could moreover be used to compare the ability of
Pitx and Tpit as well as Smad proteins to tether on POMC promoter sequences in Bmp
treated and non-treated AtT-20 celis.
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CHAPTER5- CONCLUSION
As a first step towards the deveiopment of a coherent model for the role of
Bmp/Tgf- signais in corticotroph celi differentiation, my Master’s proj cet investigated the
actions of Bmp signaling on POMC expression and promoter activity in the AtT-20
corticotroph ccli une model. I was abie to show that rBmp-4 stimulation of AtT-20 celis
represses endogenous POMC mRNA as weil as FOMC-luc reporter activity. The rnost
prevalent Bmp signal transduction rnechanism implicates ligand binding to Alk-3 and -6
receptors, and activation of Smadl/5/8 intraceÏlular mediators. In agreement with this
model, I showed that inhibitory Bmp effects on POMC promoter activity arc either
reconstituted or enhanced, respectiveiy, by co-expression of constitutiveiy active forms of
the Bmp receptors, Alk-3 (Q223D) and Alk-6 (Q203D), or by co-expression of Smadl and
Smad4. In addition, Bmp-dependent repression of POMC could be reversed by the
expression of inhibitory Smad6 or Smad7 factors.
The search for Bmp-responsive elernents within the mouse POMC promoter proved
to be a complex task. When the basal activities of the distal, central or proximai POMC
promoter regions were examined separateiy for their response to rBmp-4 treatments in AtT
20 celis, none were significantly repressed. These resuits suggest that Bmp signais might
be targeting a transcriptional complex on the POMC promoter that is made up of multiple
regulatory eiements. Previous work in our laboratory on POMC promoter organization
demonstrated that most of its activity is generated by synergistic interactions between distal
and central regions. Interestingly, only the combined activity of distal and central prornoter
regions was significantly repressed in AtT-20 celis following rBmp4-treatments.
The regulatory mechanism for celi-specific transcription of the POMC gene
implicates synergistic interactions between distal NeuroD 1 /BETA2 bHLH heterodimers,
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and central Pitxl homeobox and Tpit T-box factors. Findings from the latter part of my
work extend these studies to show that Smad-mediated Bmp signaling pathways might be
acting through Pitx and Tpit transcription factors to block or downregulate POMC
expression in AtT-20 corticotroph cells. How Bmp-activated Smads interfere with the
activity of Pitx and Tpit and hence POMC expression remains to be clearly understood. In
heteroÏogous cells, I show that Bmp signals can block transcriptional synergy between Pitx
and Tpit, suggesting that the activity ofPitx and Tpit on their respective binding sites in the
central region of the POMC promoter would directly be targeted by Bmp signals. In vitro
binding studies that I performed fiirthermore support a mechanism of Bmp action that
would see the recruitment of Bmp-activated Smads to the promoter through protein:protein
interactions with Pitx and Tpit factors. Preliminary EMSA results indicate that Smadl but
flot Smad4 binds to yet undefined POMC promoter sequences in proximity to Pitx and Tpit
regulatory elements. Smadl-tethering to POMC might enable the Smad complex to
negatively regulate Pitx/Tpit synergistic activities by either interfering with their respective
DNA binding activities, or rather by modulating their association with other POMC
specific or general co-factors. The observation that maximal Brnp inhibition of POMC
promoter activity requires that both distal and central domains be present and intact
suggests that Bmp signaling, through Pitx andlor Tpit recruitment, might interfere with the
activity of a bigger transcriptional complex composed of both central and distal regulatory
elements. Preliminary work in our laboratory suggests that Tpit activity in the central
region of the promoter is greatly enhanced by co-activators previously thought to increase
distal-specific transcriptional activity. A combination of EMSA and chromatin
immunoprecipitation techniques should be helpful in further delineating the molecular basis
of Smad-mediated Bmp repression of POMC expression, and the rote both central and
distal parts ofthe POMC promoter play in the mediation ofBmp inhibitory effects.
10$
A useful tool in my analysis ofthe role Bmp signais play in the regulation ofFOMC
expression tumed out to be the AtT-20 corticotroph celi une, seeing that it endogenously
expresses NeuroD 1, Tpit and Pitx celi-specific regulators of POMC activity and moreover
responds to Brnp signaling. RT-PCR studies revealed the incidence of Bmp-specific type I
receptor as well as Bmp-7 expression in AtT-20 celis, suggesting that these ceils might
endogenously harbour some Bmp-7 signaling activity that would maintain POMC
expression in a slightly repressed state. Evidence to support the latter idea came with the
overexpression of Smad6 or Smad7 inhibitors in AtT-20 ceils, which in itself led to the
induction of POMC promoter activity. As appropriate as AtT-20 celis have been to study
the moiecular basis of POMC repression by Bmp/Smadl signaling, their worth as a model
to study corticotroph differentiation is limited.
Stili, in showing that the Bmp/Smadl signaling pathway represses the expression of
POMC in AtT-20 celis, which is in support of the previously reported downregulation of
ACTH expression in Rathke’s Pouch explants cuitured in the presence of Bmp2-coated
beads, it would appear that Bmp-2 andlor Bmp-4 signais expressed eariy on during
pituitary organogenesis wouid be acting to negatively regulate POMC expression. Tndeed,
Bmp signais could be set in piace in the developing pituitary to correctiy tum on the
corticotroph differentiation program and/or to downreguiate POMC expression in
differentiated corticotrophs. Reievant evidence for such biologicai functions of Bmp
signais in corticotroph differentiation could corne from studying the spatiotemporal activity
ofBrnp signaling pathways in the developing pituitary. Bmp activity in mice pituitaries of
different developmental stages couid be assayed by immunohistochemical anaiyses using
antibodies that are specific for the phosphorylated form of Smadl, Smad5 andlor Smad8. I
attempted such studies but could detect no activity of phosphorylated Smadl in the
pituitary, while signal was obtained in sorne tissues in elO.5, ell.5 e12.5 and e14.5 mice.
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These negative resuits couid mean that the iess characterized Smad5 or Smad8 proteins act
downstream of Bmp signais in the early developing pituitary to negatively regulate FOMC
expression, or that Smad-mediated Bmp signaling pathways play a reguiatory role in
FOMC expression oniy later on in the developing embryo or in the aduit stage. If Smad
activity were to be detected in the pituitary, it wouid be interesting to determine through co
staining techniques and hormone markers which population ofpituitary ceils harbors active
Bmp signaling pathways. Phosphorylated-Smad and ACTH co-staining for example would
be a strong indication that Bmp signais are indeed working in corticotroph ceils to repress
POMC expression. A peak of Bmp/Smad activity in corticotrophs at e12 or earlier, would
be an indication that Bmp piays a roie in timing the onset of corticotroph differentiation,
while the detection of Bmp signaling activity at later stages of pituitary deveiopment would
support a rote for Bmp in the maintenance of the corticotroph differentiated phenotype.
The possibility that Bmp signals do not function in corticotrophs, but rather act in the rest
ofpituitary ceils to altogether block the expression of FOMC, should not be excluded.
Brnp gain-of-function or gene-inactivation studies that specificaiiy target the
pituitary would constitute a problematic approach to understanding the biological effects of
Bmp signaling on pituitary ceii differentiation since Bmp signais are required for proper
pituitary organogenesis. More informative perhaps is studying the biologicai roie of
distinct Bmp-specific Smads in the pituitary, supposing that different Smads are implicated
in organogenesis and ceii differentiations decisions.
Tgf-f3 signaling appears to be highly reguiated in deveiopmental processes.
Deficient expression of Smad7 for example has recentiy been impiicated in the
pathogenesis of scieroderma, which is moreover associated with high levels of Smad3
activity (57). h rny work, Bmp action in AtT-20 celis was efficiently counteracted by the
transient overexpression of Samd6 or Smad7. It would be interesting to assess the
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expression pattem and biological functions of such Bmp or Smad inhibitors in the pituitary.
Bmp/Srnad inhibitors would function in corticotroph ceils to counteract Bmp inhibitory
effects on POMC expression and hence allow corticotroph differentiation to begin, or
simply permit the upregulation of FOMC expression in response to some physiological cue.
An interplay of positive and negative inputs into Bmp signaling pathways might serve to
regulate POMC expression ail along the life of a corticotroph celi. It is also possible that
the normal control Bmp pathways exercise on FOMC transcriptional processes could
become disregulated and subsequently resuit in malignant transformations. Investigating
the molecular basis of Bmp participation in corticotroph celi phenotype determination and
differentiation could give us dues as to the implications of these same pathways in
tumorigenesis.
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